"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 912787 A,137-205-542-693-786,1909-02-16,1909,US 1908/0415379 A,1908-02-11,US 1908/0415379 A,1908-02-11,ICE-CREAM FREEZER.,,BELKNAP THOMAS M,BELKNAP THOMAS M,,https://lens.org/137-205-542-693-786,Granted Patent,no,0,0,1,1,0,A23G9/18;;Y10S165/087;;A23G9/18;;Y10S165/087,,,0,0,,,,EXPIRED
2,US,A,US 1024389 A,010-628-791-411-013,1912-04-23,1912,US 1910/0583699 A,1910-09-24,US 1910/0583699 A,1910-09-24,POSTAGE STAMPING AND RECORDING APPARATUS.,,BELKNAP THOMAS M,BELKNAP THOMAS M,,https://lens.org/010-628-791-411-013,Granted Patent,no,0,1,1,1,0,B41K1/40;;B41K1/40,,,0,0,,,,EXPIRED
3,US,A1,US 2019/0137258 A1,071-752-042-010-301,2019-05-09,2019,US 201816056471 A,2018-08-06,US 201816056471 A;;US 201762541388 P,2017-08-04,"System and Method for Filling Apparel with Gases, Fluids, or Fluid-Like Solids to Enable the Accurate Three-Dimensional Capture of Apparel by Three-Dimensional Scanning and Stereo Photogrammetry","The present invention provides a system for accurate three-dimensional (3D) capture of apparel by 3D scanning and stereo photogrammetry. One or more flexible deflated bladders are inserted into an apparel and inflated by a filling media source. The bladder is inflated to measure at least one of size of the apparel, tensile strength of the fabric of the apparel, or cross section perimeter of the apparel. A rotating structure is anchored onto the stable structure to uniformly rotate all the fixed points of the apparel. One or more 3D scanners are configured to scan the inflated apparel on the stable structure and export the scanned data to one or more software applications. The processor retrieves the 3D scanned dimensional data from a searchable database and compares the given apparel's dimensions with one or more apparels' dimensions in the database to provide the customer with size recommendation via a display.",CLOTHSCAN LLC,BELKNAP JOHN THOMAS;;SHIMADA KENJI,,https://lens.org/071-752-042-010-301,Patent Application,yes,0,3,2,2,0,G01B11/2513;;G01B11/2545;;G06Q30/0621;;G01B11/02;;G01B11/24;;G06T7/62;;H04N13/282;;G06T2207/10012;;G06Q30/0621;;A41D1/06;;A41B1/00;;G06F16/538;;G01B11/2513;;G01B11/2545,G01B11/02;;G01B11/24;;G06F16/538;;G06Q30/06;;G06T7/62;;H04N13/282,,0,0,,,,ACTIVE
4,US,B2,US 10436575 B2,004-541-857-938-039,2019-10-08,2019,US 201816056471 A,2018-08-06,US 201816056471 A;;US 201762541388 P,2017-08-04,"Systems and method for filling apparel with gases, fluids, or fluid-like solids to enable the accurate three-dimensional capture of apparel by three-dimensional scanning and stereo photogrammetry","The present invention provides a system for accurate three-dimensional (3D) capture of apparel by 3D scanning and stereo photogrammetry. One or more flexible deflated bladders are inserted into an apparel and inflated by a filling media source. The bladder is inflated to measure at least one of size of the apparel, tensile strength of the fabric of the apparel, or cross section perimeter of the apparel. A rotating structure is anchored onto the stable structure to uniformly rotate all the fixed points of the apparel. One or more 3D scanners are configured to scan the inflated apparel on the stable structure and export the scanned data to one or more software applications. The processor retrieves the 3D scanned dimensional data from a searchable database and compares the given apparel's dimensions with one or more apparels' dimensions in the database to provide the customer with size recommendation via a display.",CLOTHSCAN LLC,BELKNAP JOHN THOMAS;;SHIMADA KENJI,,https://lens.org/004-541-857-938-039,Granted Patent,yes,1,0,2,2,0,G01B11/2513;;G01B11/2545;;G06Q30/0621;;G01B11/02;;G01B11/24;;G06T7/62;;H04N13/282;;G06T2207/10012;;G06Q30/0621;;A41D1/06;;A41B1/00;;G06F16/538;;G01B11/2513;;G01B11/2545,H04N17/00;;A41B1/00;;A41D1/06;;G01B11/02;;G01B11/24;;G01B11/25;;G06F16/538;;G06Q30/06;;G06T7/62;;H04N13/282;;H04N17/06,,0,0,,,,ACTIVE
5,AU,B2,AU 2014/384634 B2,009-510-099-064-271,2017-05-11,2017,AU 2014/384634 A,2014-12-22,US 201414247776 A;;US 201461945805 P;;US 2014/0072004 W,2014-02-27,Systems and methods for providing a user with a set of interactivity features on a user device,"Providing a user with an interactive user interface that may fully enable interactions regardless of connectivity status may be provided. In some embodiments, one or more content items may be selected by a user of the user devices and may be queued for upload to a content management system. The content items may be organized into one or more collections of content items with other content items already stored in a user account on the content management system, such as images having similar geo-temporal characteristics. A set of interactivity features may be available to the user for interacting with the queued content item. This may provide the user with the seamless feeling as if the content items have been uploaded to the content management system and the user may be interacting with the content items on the content management system, even if the upload has not been completed.",DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,,https://lens.org/009-510-099-064-271,Granted Patent,no,3,0,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,H04N21/24;;G06F17/30;;H04L29/08;;H04N21/45;;H04N21/65,,0,0,,,,ACTIVE
6,EP,B1,EP 3111653 B1,172-769-888-379-818,2019-10-16,2019,EP 14827974 A,2014-12-22,US 201461945805 P;;US 201414247776 A;;US 2014/0072004 W,2014-02-27,SYSTEMS AND METHODS FOR PROVIDING A USER WITH A SET OF INTERACTIVITY FEATURES ON A USER DEVICE,,DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,,https://lens.org/172-769-888-379-818,Granted Patent,yes,2,0,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,G06F3/0484;;G06F16/11;;G06F16/27;;G06F16/28;;G06F16/51;;H04L12/26;;H04L29/08;;H04N21/24;;H04N21/45;;H04N21/65,,0,0,,,,ACTIVE
7,US,B2,US 10235444 B2,150-928-626-789-187,2019-03-19,2019,US 201615174789 A,2016-06-06,US 201615174789 A;;US 201414247776 A;;US 201461945805 P,2014-02-27,Systems and methods for providing a user with a set of interactivity features locally on a user device,"Providing a user with an interactive user interface that may fully enable interactions regardless of connectivity status may be provided. In some embodiments, one or more content items may be selected by a user of the user devices and may be queued for upload to a content management system. The content items may be organized into one or more collections of content items with other content items already stored in a user account on the content management system, such as images having similar geo-temporal characteristics. A set of interactivity features may be available to the user for interacting with the queued content item. This may provide the user with the seamless feeling as if the content items have been uploaded to the content management system and the user may be interacting with the content items on the content management system, even if the upload has not been completed.",DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,DROPBOX INC (2014-04-01),https://lens.org/150-928-626-789-187,Granted Patent,yes,88,13,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,H04L29/08;;G06F3/0484;;H04L12/26,,19,2,134-359-742-244-38X;;077-001-996-122-196,10.1145/1277741.1277762;;10.1145/957092.957093,"Examination Report as received in European application No. 14827976.3 dated Aug. 22, 2017.;;Eliza Kern, “Albumatic and Cluster try a fresh take on an old problem: group photo-sharing”; Feb. 27, 2013 Gigaorn: URL: http://gigaom.com/2013/02/27/albumatic-and-cluster-try-a-fresh-take-on-an-old-problem-group-photo-sharing/.;;Sarah Perez, “Cluster Brings Simple Group Photo-Sharing to Android”; Oct. 14, 2013 Techcrunch.com; URL: http://techcrunch.com/2013/10/14/cluster-brings-simple-social-photo-sharing-to-android/.;;Tye Rattenbury, Nathaniel Good and Mor Naarnan, “Towards Automatic Extraction of Event and Place Semantics from Flickr Tags”; SIGIR'07 (Special Interest Group on Information Retrieval) Jul. 23-27, 2007.;;Matthew Cooper, Jonathan Foote, Andreas Girgensohn, and Lynn Wilcox, “Temporal Event Clustering for Digital Photo Collections”; MM'03 (2003 11th Annual ACM International Conference on Multimedia) Nov. 2-8, 2003.;;International Search Report issued in PCT/US14/72006 dated Mar. 6, 2015.;;International Search Report issued in PCT/US14/72004 dated Mar. 10, 2015.;;U.S. Appl. No. 14/247,776, Jul. 28, 2014, Office Action.;;U.S. Appl. No. 14/247,776, Jan. 30, 2015, Office Action.;;U.S. Appl. No. 14/247,776, Oct. 21, 2015, Office Action.;;U.S. Appl. No. 14/247,776, Mar. 7, 2016, Notice of Allowance.;;U.S. Appl. No. 14/247,776, May 20, 2016, Notice of Allowance.;;U.S. Appl. No. 14/247,840, Oct. 7, 2014, Office Action.;;U.S. Appl. No. 14/247,840, Jan. 17, 2015, Notice of Allowance.;;Examination Report as received in European application No. 14827974.8 dated Feb. 28, 2018.;;U.S. Appl. No. 14/741,277, Jun. 2, 2017, Office Action.;;Uwe Hansmann et al., “SyncML: Synchronizing and Managing Your Mobile Data,” Sep. 19, 2002, Prentice Hall, ISBN: 978-0-13-009369-1.;;U.S. Appl. No. 14/247,840, Jun. 17, 2015, Notice of Allowance.;;U.S. Appl. No. 14/741,277, Nov. 30, 2017, Notice of Allowance.",ACTIVE
8,US,A1,US 2015/0244794 A1,054-077-138-065-101,2015-08-27,2015,US 201414247776 A,2014-04-08,US 201414247776 A;;US 201461945805 P,2014-02-27,SYSTEMS AND METHODS FOR PROVIDING A USER WITH A SET OF INTERACTIVITY FEATURES LOCALLY ON A USER DEVICE,"Providing a user with an interactive user interface that may fully enable interactions regardless of connectivity status may be provided. In some embodiments, one or more content items may be selected by a user of the user devices and may be queued for upload to a content management system. The content items may be organized into one or more collections of content items with other content items already stored in a user account on the content management system, such as images having similar geo-temporal characteristics. A set of interactivity features may be available to the user for interacting with the queued content item. This may provide the user with the seamless feeling as if the content items have been uploaded to the content management system and the user may be interacting with the content items on the content management system, even if the upload has not been completed.",DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,DROPBOX INC (2014-04-01),https://lens.org/054-077-138-065-101,Patent Application,yes,16,67,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,H04L29/08,,0,0,,,,ACTIVE
9,WO,A1,WO 2015/130397 A1,130-108-540-724-885,2015-09-03,2015,US 2014/0072004 W,2014-12-22,US 201461945805 P;;US 201414247776 A,2014-02-27,SYSTEMS AND METHODS FOR PROVIDING A USER WITH A SET OF INTERACTIVITY FEATURES ON A USER DEVICE,"Providing a user with an interactive user interface that may fully enable interactions regardless of connectivity status may be provided. In some embodiments, one or more content items may be selected by a user of the user devices and may be queued for upload to a content management system. The content items may be organized into one or more collections of content items with other content items already stored in a user account on the content management system, such as images having similar geo-temporal characteristics. A set of interactivity features may be available to the user for interacting with the queued content item. This may provide the user with the seamless feeling as if the content items have been uploaded to the content management system and the user may be interacting with the content items on the content management system, even if the upload has not been completed.",DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,,https://lens.org/130-108-540-724-885,Patent Application,yes,5,1,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,G06F17/30;;H04N21/24;;H04L29/08;;H04N21/45;;H04N21/65,,0,0,,,,PENDING
10,AU,A1,AU 2014/384634 A1,184-120-946-984-792,2016-09-08,2016,AU 2014/384634 A,2014-12-22,US 201414247776 A;;US 201461945805 P;;US 2014/0072004 W,2014-02-27,Systems and methods for providing a user with a set of interactivity features on a user device,"Providing a user with an interactive user interface that may fully enable interactions regardless of connectivity status may be provided. In some embodiments, one or more content items may be selected by a user of the user devices and may be queued for upload to a content management system. The content items may be organized into one or more collections of content items with other content items already stored in a user account on the content management system, such as images having similar geo-temporal characteristics. A set of interactivity features may be available to the user for interacting with the queued content item. This may provide the user with the seamless feeling as if the content items have been uploaded to the content management system and the user may be interacting with the content items on the content management system, even if the upload has not been completed.",DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,,https://lens.org/184-120-946-984-792,Patent Application,no,0,0,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,H04N21/24;;G06F17/30;;H04L29/08;;H04N21/45;;H04N21/65,,0,0,,,,ACTIVE
11,EP,A1,EP 3111653 A1,092-626-147-253-662,2017-01-04,2017,EP 14827974 A,2014-12-22,US 201461945805 P;;US 201414247776 A;;US 2014/0072004 W,2014-02-27,SYSTEMS AND METHODS FOR PROVIDING A USER WITH A SET OF INTERACTIVITY FEATURES ON A USER DEVICE,,DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,,https://lens.org/092-626-147-253-662,Patent Application,yes,0,0,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,G06F3/0484;;G06F16/11;;G06F16/27;;G06F16/28;;G06F16/51;;H04L12/26;;H04L29/08;;H04N21/24;;H04N21/45;;H04N21/65,,0,0,,,,ACTIVE
12,US,B2,US 9462054 B2,147-634-551-843-57X,2016-10-04,2016,US 201414247776 A,2014-04-08,US 201414247776 A;;US 201461945805 P,2014-02-27,Systems and methods for providing a user with a set of interactivity features locally on a user device,"Providing a user with an interactive user interface that may fully enable interactions regardless of connectivity status may be provided. In some embodiments, one or more content items may be selected by a user of the user devices and may be queued for upload to a content management system. The content items may be organized into one or more collections of content items with other content items already stored in a user account on the content management system, such as images having similar geo-temporal characteristics. A set of interactivity features may be available to the user for interacting with the queued content item. This may provide the user with the seamless feeling as if the content items have been uploaded to the content management system and the user may be interacting with the content items on the content management system, even if the upload has not been completed.",DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,DROPBOX INC (2014-04-01),https://lens.org/147-634-551-843-57X,Granted Patent,yes,59,19,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,H04L29/08;;G06F17/30,,8,2,134-359-742-244-38X;;077-001-996-122-196,10.1145/1277741.1277762;;10.1145/957092.957093,"Eliza Kern, ""Albumatic and Cluster try a fresh take on an old problem: group photo-sharing""; Feb. 27, 2013 Gigaorn: URL: http://gigaom.com/2013/02/27/albumatic-and-cluster-try-a-fresh-take-on-an-old-problem-group-photo-sharing/.;;Sarah Perez, ""Cluster Brings Simple Group Photo-Sharing To Android""; Oct. 14, 2013 Techcrunch.com; URL: http://techcrunch.com/2013/10/14/cluster-brings-simple-social-photo-sharing-to-android/.;;Tye Rattenbury, Nathaniel Good and Mor Naarnan, ""Towards Automatic Extraction of Event and Place Semantics from Flickr Tags""; SIGIR'07 (Special Interest Group On Information Retrieval) Jul. 23-27, 2007.;;Matthew Cooper, Jonathan Foote, Andreas Girgensohn, and Lynn Wilcox, ""Temporal Event Clustering for Digital Photo Collections""; MM'03 (2003 11th Annual ACM International Conference on Multimedia) Nov. 2-8, 2003.;;International Search Report issued in PCT/US14/72006 on Mar. 6, 2015.;;International Search Report issued in PCT/US14/72004 on Mar. 10, 2015.;;U.S. Appl. No. 14/247,840, mailed Oct. 7, 2014, Office Action.;;U.S. Appl. No. 14/247,840, mailed Jun. 17, 2015, Notice of Allowance.",ACTIVE
13,US,A1,US 2016/0314187 A1,021-655-274-126-110,2016-10-27,2016,US 201615174789 A,2016-06-06,US 201615174789 A;;US 201414247776 A;;US 201461945805 P,2014-02-27,SYSTEMS AND METHODS FOR PROVIDING A USER WITH A SET OF INTERACTIVITY FEATURES LOCALLY ON A USER DEVICE,"Providing a user with an interactive user interface that may fully enable interactions regardless of connectivity status may be provided. In some embodiments, one or more content items may be selected by a user of the user devices and may be queued for upload to a content management system. The content items may be organized into one or more collections of content items with other content items already stored in a user account on the content management system, such as images having similar geo-temporal characteristics. A set of interactivity features may be available to the user for interacting with the queued content item. This may provide the user with the seamless feeling as if the content items have been uploaded to the content management system and the user may be interacting with the content items on the content management system, even if the upload has not been completed.",DROPBOX INC,POLETTO STEPHEN;;BELKNAP PETER;;KLEINPETER THOMAS,DROPBOX INC (2014-04-01),https://lens.org/021-655-274-126-110,Patent Application,yes,0,15,11,11,0,H04L67/06;;G06F16/285;;G06F16/51;;G06F16/113;;H04L67/535;;H04L67/1085;;G06F16/285;;G06F16/27;;G06F16/51;;G06F16/113;;H04L67/06;;H04L65/40;;H04L67/535;;H04L67/1095;;G06F3/04842;;H04L43/0811;;H04L43/16,G06F17/30;;G06F3/0484;;H04L12/26;;H04L29/08,,0,0,,,,ACTIVE
14,US,S,US D0778064 S,169-565-175-998-544,2017-02-07,2017,US 201329461384 F,2013-07-23,US 201329461384 F,2013-07-23,Skin cleansing device,,OWEN THOMAS EDWARD;;WOO-KIM CHONG WON JESSICA;;WONG JENNY;;BELKNAP JENNY;;LAPOSTA RICHARD;;CECERE LOIS;;ELC MAN LLC,OWEN THOMAS EDWARD;;WOO-KIM CHONG WON JESSICA;;WONG JENNY;;BELKNAP JENNY;;LAPOSTA RICHARD;;CECERE LOIS,ELC MANAGEMENT LLC (2013-09-24),https://lens.org/169-565-175-998-544,Design Right,no,0,15,6,6,0,,,0402;;D 4127;;D4/132,0,0,,,,ACTIVE
15,US,A,US 5586264 A,076-301-686-406-415,1996-12-17,1996,US 30261994 A,1994-09-08,US 30261994 A,1994-09-08,Video optimized media streamer with cache management,"A data storage system includes a mass storage unit storing a data entity, such as a digital representation of a video presentation, that is partitioned into a plurality N of temporally-ordered segments. A data buffer is bidirectionally coupled to the mass storage unit for storing up to M of the temporally-ordered segments, wherein M is less than N. The data buffer has an output for outputting stored ones of the temporally-ordered segments. The data storage system further includes a data buffer manager for scheduling transfers of individual ones of the temporally-ordered segments between the mass storage unit and the data buffer. The data buffer manager schedules the transfers in accordance with at least a predicted time that an individual one of the temporally-ordered segments will be required to be output from the data buffer. When employed with a media streamer (10) distributed data buffer management techniques are employed for selecting blocks to be retained in a buffer memory, either in a storage node (16, 17) or in a communication node (14). These techniques rely on the predictable nature of the video data stream, and thus are enabled to predict the future requirements for a given one of the data blocks.",IBM,BELKNAP WILLIAM R;;HENLEY MARTHA R;;FALCON JR LORENZO;;FRAYNE THOMAS E;;LUO MEI-LAN;;SAXENA ASHOK R,INTERNATIONAL BUSINESS MACHINES CORPORATION (1994-10-21),https://lens.org/076-301-686-406-415,Granted Patent,yes,19,552,5,5,0,G06F3/0601;;G06F12/0866;;G06F3/0656;;G06F3/0673;;G06F3/0601;;G06F12/0866;;G06F3/0656;;G06F3/0673,G06F3/06;;G06F12/00;;G06F17/30;;G06F12/08,395/200.08;;395/800;;395/872;;395/834;;348/7;;X364DIG  1;;X364DIG  2;;364/239;;364/238.3;;364/241.9;;364/222.2;;364/939;;364/260;;364/242.94,5,1,028-198-371-561-855,10.1109/35.281582,"European Search Report, Application No. EP 95 30 5966, dated 29 Dec. 1995.;;Article entitled Interactive Video On Demand by Daniel Deloddere et al. as appeared in IEEE Communications Magazine, May 1994, pp. 82 88.;;Intel Scalable Multi server Technology for Interactive Multimedia Applications May, 1994, 1994 Intel Corporation, pp. 3 15.;;Architectures for Video Servers by Manu Thapar and Bill Koerner, Hewlett Packard, 1994 NCTA Technical Papers, pp. 141 148.;;Allicat (0664) S10 SCSI Direct Access Storage Device Functional Specification Release 4.50, Document No. AS01 0003 00, formatted on May 6, 1993 IBM Corporation, pp. 1 291.",EXPIRED
16,CA,A1,CA 2153444 A1,040-112-077-714-069,1996-03-09,1996,CA 2153444 A,1995-07-07,US 30261994 A,1994-09-08,VIDEO OPTIMIZED MEDIA STREAMER WITH CACHE MANAGEMENT,"A data storage system includes a mass storage unit storing a data entity, such as a digital representation of a video presentation, that is partitioned into a plurality N of temporally-ordered segments. A data buffer is bidirectionally coupled to the mass storage unit for storing up to M of the temporally-ordered segments, wherein M is less than N. The data buffer has an output for outputting stored ones of the temporally-ordered segments. The data storage system further includes a data buffer manager for scheduling transfers of individual ones of the temporally-ordered segments between the mass storage unit and the data buffer. The data buffer manager schedules the transfers in accordance with at least a predicted time that an individual one of the temporally-ordered segments will be required to be output from the data buffer. When employed with a media streamer distributed data buffer management techniques are employed for selecting blocks to be retained in a buffer memory, either in a storage node or in a communication node. These techniques rely on the predictable nature of the video data stream, and thus are enabled to predict the future requirements for a given one of the data blocks.",IBM,BELKNAP WILLIAM RUSSELL;;HENLEY MARTHA R;;FALCON LORENZO JR;;FRAYNE THOMAS E;;LUO MEI-LAN;;SAXENA ASHOK RAJ,,https://lens.org/040-112-077-714-069,Patent Application,no,0,0,5,5,0,G06F3/0601;;G06F12/0866;;G06F3/0656;;G06F3/0673;;G06F3/0601;;G06F12/0866;;G06F3/0656;;G06F3/0673,G06F12/08;;G06F3/06;;G06F12/00;;G06F17/30,,0,0,,,,DISCONTINUED
17,ES,T3,ES 2312929 T3,073-686-195-804-479,2009-03-01,2009,ES 04252643 T,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,FORMAS DE DOSIFICACION DE AZITROMICINA CON EFECTOS SECUNDARIOS REDUCIDOS.,"Una forma de dosificación oral que comprende: a) una cantidad eficaz de un agente alcalinizante; y b) multipartículas que comprenden i) azitromicina; ii) una mezcla de monobehenato de glicerilo, dibehenato de glicerilo y tribehenato de glicerilo; y iii) un poloxámero.",PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP,,https://lens.org/073-686-195-804-479,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
18,ES,T3,ES 2284871 T3,113-928-127-910-876,2007-11-16,2007,ES 02733019 T,2002-05-13,US 30026101 P,2001-06-22,COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UNA DISPERSION SOLIDA DE FARMACO POCO SOLUBLE Y UN POLIMERO POTENCIADOR DE LA SOLUBILIDAD.,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN,,https://lens.org/113-928-127-910-876,Granted Patent,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,A61K47/38;;C07D215/42;;A61K9/08;;A61K9/14;;A61K31/40;;A61K31/47;;A61K31/497;;A61K31/498;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/42;;A61K47/44,,0,0,,,,EXPIRED
19,EP,A1,EP 0702491 A1,037-922-288-429-619,1996-03-20,1996,EP 95305966 A,1995-08-25,US 30261994 A,1994-09-08,Video optimized media streamer with cache management,"A data storage system includes a mass storage unit storing a data entity, such as a digital representation of a video presentation, that is partitioned into a plurality N of temporally-ordered segments. A data buffer is bidirectionally coupled to the mass storage unit for storing up to M of the temporally-ordered segments, wherein M is less than N. The data buffer has an output for outputting stored ones of the temporally-ordered segments. The data storage system further includes a data buffer manager for scheduling transfers of individual ones of the temporally-ordered segments between the mass storage unit and the data buffer. The data buffer manager schedules the transfers in accordance with at least a predicted time that an individual one of the temporally-ordered segments will be required to be output from the data buffer. When employed with a media streamer (10) distributed data buffer management techniques are employed for selecting blocks to be retained in a buffer memory, either in a storage node (16, 17) or in a communication node (14). These techniques rely on the predictable nature of the video data stream, and thus are enabled to predict the future requirements for a given one of the data blocks.",IBM,BELKNAP WILLIAM RUSSELL;;HENLEY MARTHA R;;FALCON LORENZO JR;;FRAYNE THOMAS E;;LUO MEI-LAN;;SAXENA ASHOK RAJ,,https://lens.org/037-922-288-429-619,Patent Application,yes,5,20,5,5,0,G06F3/0601;;G06F12/0866;;G06F3/0656;;G06F3/0673;;G06F3/0601;;G06F12/0866;;G06F3/0656;;G06F3/0673,G06F12/08;;G06F3/06;;G06F12/00;;G06F17/30,,1,1,028-198-371-561-855,10.1109/35.281582,"D. DELODDERE ET AL.: ""Interactive Video on Demand"", IEEE COMMUNICATIONS MAGAZINE, vol. 32, no. 5, May 1994 (1994-05-01), PISCATAWAY, NJ US, pages 82 - 88, XP000451098",DISCONTINUED
20,PA,A1,PA 8611501 A1,159-425-785-956-109,2005-08-04,2005,PA 8611501 A,2004-09-08,US 76334004 A;;US 52708403 P,2003-12-04,FORMAS DE DOSIFICACION DE AZITROMICINA CON EFECTOS SECUNDARIOS REDUCIDOS,"UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE. PREFERIBLEMENTE, DICHA FORMA DE DOSIFICACION ORAL COMPRENDE UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE Y UN MULTIPARTICULADO DE AZITROMICINA EN EL QUE DICHO MULTIPARTICULADO COMPRENDE AZITROMICINA, UNA MEZCLA DE MONOBEHENATO DE GLICERILO, DIBEHENATO DE GLICERILO Y TRIBEHENATO DE GLICERILO Y UN POLOXAMERO. TIPICAMENTE, LA FORMA DE DOSIFICACION ORAL INCLUYE CUALQUIER MEDIO DE ADMINISTRACION ORAL ADECUADO TAL COMO UN POLVO PARA SUSPENSION ORAL, UN ENVASE O SOBRECITO DE DOSIS UNITARIA, UN COMPRIMIDO O UNA CAPSULA. ADEMAS SE DESCRIBE UNA SUSPENSION ORAL QUE COMPRENDE AZITROMICINA, UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE Y UN VEHICULO. PREFERIBLEMENTE, LA AZITROMICINA ESTA EN FORMA MULTIPARTICULADA EN LA QUE DICHO MULTIPARTICULADO COMPRENDE AZITROMICINA, UNA MEZCLA DE MONOBEHENATO DE GLICERILO, DIBEHENATO DE GLICERILO Y TRIBEHENATO DE GLICERILO Y UN POLOXAMERO. TAMBIEN SE DESCRIBE UN PROCEDIMIENTO PARA REDUCIR LOS EFECTOS SECUNDARIOS GASTROINTESTINALES ASOCIADOS A LA ADMINISTRACION DE AZITROMICINA A UN MAMIFERO, QUE COMPRENDE LA ADMINISTRACION DE FORMA CONTIGUA DE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE A DICHO MAMIFERO EN EL QUE LA FRECUENCIA DE EFECTOS SECUNDARIOS GASTROINTESTINALES ES MENOR QUE LA QUE SE EXPERIMENTA ADMINISTRANDO UNA DOSIS IGUAL DE AZITROMICINA SIN DICHO AGENTE ALCALINIZANTE. ADEMAS SE DESCRIBE UN PROCEDIMIENTO PARA TRATAR UNA INFECCION BACTERIANA O PROTOZOARIA EN UN MAMIFERO QUE LO NECESITE QUE COMPRENDE LA ADMINISTRACION DE FORMA CONTIGUA A DICHO MAMIFERO DE UNA DOSIS UNICA DE UNA FORMA DE DOSIFICACION ORAL EN LA QUE DICHA FORMA DE DOSIFICACION ORAL COMPRENDE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE. ADICIONALMENTE SE DESCRIBEN MULTIPARTICULADOS DE AZITROMICINA QUE COMPRENDEN AZITROMICINA, UN TENSIOACTIVO; Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE.",PFIZER PROD INC,APPEL LEAH ELIZABETH;;THOMBRE AVINASH GOVIND;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;CREW MARSHALL DAVID;;HAGEN TOMOTHY ARTHUR;;LO JULIAN BELKNAP,,https://lens.org/159-425-785-956-109,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04;;C07G11/00,,0,0,,,,PENDING
21,CN,A,CN 117203484 A,159-342-616-637-699,2023-12-08,2023,CN 202280028583 A,2022-04-13,US 202163174509 P;;US 2022/0024712 W,2021-04-13,Capacitive seat sensor and methods of making and using same,"In an example, a vehicle seat sensor system includes a vehicle seat, a flexible seat sensor, and an electronic unit. The vehicle seat includes a seat surface. The flexible seat sensor is disposed within a deformable distance from a seat surface and includes one or more signal electrodes, one or more ground electrodes, one or more dielectric layers, and one or more capacitors. Each capacitor is formed from a combination of a corresponding signal electrode and a corresponding ground electrode, with a corresponding dielectric layer positioned between the corresponding signal electrode and the corresponding ground electrode. The electronic unit is connected to the flexible seat sensor and is configured to be in electrical communication with the flexible seat sensor. The flexible seat sensor is configured to provide a capacitive output proportional to an amount of pressure applied to the flexible seat sensor.",NITTO CO LTD;;NITTO DENKO CORP;;NITTO BENDING TECH CO LTD,OHMTER THOMAS;;DELOS SANTOS BENEDICTE;;BELKNAP JOHN;;PORTAL JULIEN;;OATLEY CHRISTOPHER A;;JONAS JAMES K;;EISINGER CHRISTOPHER D;;BRIGGS NICHOLAS C,,https://lens.org/159-342-616-637-699,Patent Application,no,0,0,3,3,0,G01B7/22;;B60N2/00;;B60R21/01532;;G01L1/146,G01B7/16,,0,0,,,,PENDING
22,AU,A1,AU 2015/253390 A1,094-710-730-698-532,2016-11-24,2016,AU 2015/253390 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,Powered skin care device,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/094-710-730-698-532,Patent Application,no,0,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
23,KR,A,KR 20160148633 A,117-785-862-465-238,2016-12-26,2016,KR 20167032889 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,POWERED SKIN CARE DEVICE,"동력식 피부 관리 디바이스에는, 진동 모터와 디바이스의 손잡이 사이에 진동 댐퍼가 제공된다. 진동 모터는 비교적 완만한 주파수의 진동을 제공하고 브러시 헤드에는 비교적 연질의 털이 제공된다.",ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/117-785-862-465-238,Patent Application,no,0,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A46B13/02;;A46B9/06;;A46B13/00;;A47K7/04,,0,0,,,,DISCONTINUED
24,EP,B1,EP 3136924 B1,110-189-831-183-398,2021-08-04,2021,EP 15786679 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,POWERED SKIN CARE DEVICE,,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/110-189-831-183-398,Granted Patent,yes,11,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
25,CN,A,CN 106255440 A,003-449-387-907-925,2016-12-21,2016,CN 201580023369 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,Powered skin care device,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/003-449-387-907-925,Patent Application,no,10,3,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
26,EP,A1,EP 3136924 A1,170-184-919-169-412,2017-03-08,2017,EP 15786679 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,POWERED SKIN CARE DEVICE,,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/170-184-919-169-412,Patent Application,yes,0,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A47K7/03,,0,0,,,,ACTIVE
27,US,A1,US 2015/0305487 A1,183-437-856-597-042,2015-10-29,2015,US 201414264899 A,2014-04-29,US 201414264899 A,2014-04-29,Powered Skin Care Device,A powered skin care device is provided with a vibration damper between a vibrating motor and a handle of the device. The vibrating motor provides vibrations in a relatively gentle frequency and the brush head is provided with relatively soft bristles.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,ELC MANAGEMENT LLC (2014-08-27),https://lens.org/183-437-856-597-042,Patent Application,yes,28,43,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A46B13/06;;A46B13/02;;A47K7/04;;B25F5/00,,0,0,,,,ACTIVE
28,US,B2,US 9351559 B2,071-830-883-180-955,2016-05-31,2016,US 201414264853 A,2014-04-29,US 201414264853 A,2014-04-29,Powered skin care device,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,ELC MANAGEMENT LLC (2014-08-27),https://lens.org/071-830-883-180-955,Granted Patent,yes,103,15,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A46B13/02;;A46B7/04;;A46B9/06;;A46B13/00;;A47K7/04;;A61H23/02,,6,0,,,"PCT Int'l Search Report; Int'l Application No. PCT/US2015/027922; Completion Date: Jul. 17, 2015; Date of Mailing: Jan. 22, 2015.;;PCT Int'l Search Report; Int'l Application No. PCT/US2015/027933; Completion Date: Jul. 22, 2015; Date of Mailing: Jul. 22, 2015.;;PCT Int'l Search Report; Int'l Application No. PCT/US2015/027967; Completion Date: Jul. 17, 2015; Date of Mailing: Jul. 22, 2015.;;PCT Written Opin of the Int'l Searching Auth; Int'l Application No. PCT/US2015/027922; Completion Date: Jul. 17, 2015; Mailing Date: Jul. 22, 2015.;;PCT Written Opin of the Int'l Searching Auth; Int'l Application No. PCT/US2015/027933; Completion Date: Jul. 22, 2015; Mailing Date: Jul. 22, 2015.;;PCT Written Opin of the Int'l Searching Auth; Int'l Application No. PCT/US2015/027967; Completion Date: Jul. 17, 2015; Mailing Date: Jul. 22, 2015.",ACTIVE
29,KR,A,KR 20160148632 A,146-096-233-646-421,2016-12-26,2016,KR 20167032888 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,POWERED SKIN CARE DEVICE,"동력식 피부 관리 디바이스에는, 비교적 완만한 주파수를 생성하고 적어도 2개의 종류의 털을 갖는 제거 가능한 브러시 헤드를 구비하는 진동 모터가 제공된다. 제1 그룹의 털은 더욱 부드러운 세정을 위한 것이고 제2 그룹의 털은 더욱 공격적인 세정을 위한 것이다.",ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/146-096-233-646-421,Patent Application,no,0,1,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A46B9/06;;A46B13/02;;A46B13/00;;A47K7/04,,0,0,,,,DISCONTINUED
30,CA,A1,CA 2946870 A1,121-079-894-047-942,2015-11-05,2015,CA 2946870 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,POWERED SKIN CARE DEVICE,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/121-079-894-047-942,Patent Application,no,0,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
31,CA,A1,CA 2946874 A1,190-250-280-131-947,2015-11-05,2015,CA 2946874 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,POWERED SKIN CARE DEVICE,A powered skin care device is provided with a vibration damper between a vibrating motor and a handle of the device. The vibrating motor provides vibrations in a relatively gentle frequency and the brush head is provided with relatively soft bristles.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/190-250-280-131-947,Patent Application,no,0,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A47K7/03,,0,0,,,,ACTIVE
32,AU,B2,AU 2015/253390 B2,029-792-587-862-858,2018-03-01,2018,AU 2015/253390 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,Powered skin care device,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/029-792-587-862-858,Granted Patent,no,4,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
33,WO,A1,WO 2015/168076 A1,076-376-983-976-314,2015-11-05,2015,US 2015/0027922 W,2015-04-28,US 201414264853 A,2014-04-29,POWERED SKIN CARE DEVICE,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/076-376-983-976-314,Patent Application,yes,5,7,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A47K7/04;;A46B13/00,,0,0,,,,PENDING
34,EP,B1,EP 3136923 B1,165-889-491-694-628,2021-03-03,2021,EP 15786580 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,POWERED SKIN CARE DEVICE,,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/165-889-491-694-628,Granted Patent,yes,10,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A46B13/00;;A47K7/04,,0,0,,,,ACTIVE
35,EP,A4,EP 3136924 A4,060-348-606-137-970,2017-12-06,2017,EP 15786679 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,POWERED SKIN CARE DEVICE,,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/060-348-606-137-970,Search Report,no,6,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A46B13/00,,1,0,,,See also references of WO 2015168082A1,ACTIVE
36,EP,A4,EP 3136923 A4,120-002-657-947-662,2017-11-29,2017,EP 15786580 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,POWERED SKIN CARE DEVICE,,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/120-002-657-947-662,Search Report,no,5,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A46B13/00;;A47K7/04,,1,0,,,See also references of WO 2015168076A1,ACTIVE
37,ES,T3,ES 2855990 T3,116-615-436-682-231,2021-09-27,2021,ES 15786580 T,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,Dispositivo motorizado para el cuidado de la piel,"Un dispositivo motorizado para el cuidado de la piel que comprende: una carcasa (4) con un extremo proximal hueco (6) y un extremo distal cerrado (8), un eje longitudinal (10) definido desde el extremo proximal (6) al extremo distal (8), el extremo distal (8) que forma un mango (12), la carcasa (4) encierra un circuito electrónico (14) conectado a una batería (16), definiendo el extremo proximal (6) una abertura (18) orientada en un ángulo oblicuo con respecto al eje longitudinal (10), definiendo la abertura (18) una superficie anular dirigida hacia dentro (24); una plataforma de apoyo para la cabeza (26) que define una superficie exterior de apoyo (28) y una superficie interior (30); un faldón (32) que pende de la superficie interior (30) de la plataforma (26), definiendo el faldón (30) una superficie anular dirigida hacia afuera (34) dimensionada para ser recibida en relación espaciada dentro de la abertura (18) del extremo proximal de la carcasa (14), definiendo además el faldón una cavidad (36); al menos una estructura de soporte de accionamiento (38) ubicada en el faldón (32) o en la superficie interior (30) de la plataforma (26) dentro de la cavidad (36); un amortiguador de vibraciones (40) en forma de un collar elástico hecho de un material elásticamente adaptable, el amortiguador (40) conecta la superficie anular dirigida hacia adentro (24) de la carcasa (4) a la superficie anular dirigida hacia afuera (34) de la plataforma (26) para asegurar elásticamente el faldón (32) en la abertura (18) del extremo proximal hueco (6) de la carcasa (4) de manera que la superficie exterior de apoyo (28) de la plataforma (26) esté posicionada fuera de la abertura (18); un mecanismo vibratorio motorizado (42) asegurado al menos un soporte de accionamiento (38) y conectado operativamente al circuito electrónico (14) y la batería (16), el mecanismo capaz de generar vibraciones en una frecuencia de 80 Hz a 250 Hz cuando se suministra potencia desde la batería (16), el mecanismo vibratorio se fija al soporte de accionamiento (38) de manera que haga vibrar la plataforma (26); un interruptor en el circuito electrónico (14) operable para proporcionar selectivamente potencia al mecanismo vibratorio (42) desde la batería (16); un cabezal para el cuidado de la piel (46) con una base (48) que tiene un primer lado (50) que soporta una cara (52) y un segundo lado (54) adaptado para ser asegurado selectivamente a la plataforma de soporte de la cabeza (26), la cara (52) adaptada para contactar y limpiar la piel, la cara (52) tiene una primera parte (64) que se encuentra en un primer plano paralelo a un plano (22) en el que se encuentra la abertura (18), y una segunda parte (68) acostada en un segundo plano (66) formando un ángulo obtuso con la primera porción; y una primera pluralidad de cerdas (55) provistas en mechones (56) asegurados al primer lado (50) de la base (48) en una primera zona de cerdas correspondiente a la primera porción (64) de la cara (52) y una segunda pluralidad de cerdas (55) provistas en mechones (56) asegurados al primer lado (50) de la base (48) en una segunda zona de cerdas correspondiente a la segunda porción (68) de la cara (52), al menos algunos de teniendo dicha primera pluralidad de cerdas una primera rigidez y al menos parte de dicha segunda pluralidad de cerdas una segunda rigidez mayor que la primera rigidez para definir un diferencial de rigidez entre la primera parte y la segunda parte.",ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/116-615-436-682-231,Granted Patent,no,0,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
38,CN,A,CN 106231967 A,070-415-197-806-773,2016-12-14,2016,CN 201580023546 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,Powered skin care device,A powered skin care device is provided with a vibration damper between a vibrating motor and a handle of the device. The vibrating motor provides vibrations in a relatively gentle frequency and the brush head is provided with relatively soft bristles.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/070-415-197-806-773,Patent Application,no,5,2,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A47K7/03,,0,0,,,,ACTIVE
39,WO,A1,WO 2015/168082 A1,087-889-329-494-583,2015-11-05,2015,US 2015/0027933 W,2015-04-28,US 201414264899 A,2014-04-29,POWERED SKIN CARE DEVICE,A powered skin care device is provided with a vibration damper between a vibrating motor and a handle of the device. The vibrating motor provides vibrations in a relatively gentle frequency and the brush head is provided with relatively soft bristles.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/087-889-329-494-583,Patent Application,yes,5,1,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/03;;A47K7/04,,1,0,,,See also references of EP 3136924A4,PENDING
40,EP,A1,EP 3136923 A1,122-085-713-827-358,2017-03-08,2017,EP 15786580 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,POWERED SKIN CARE DEVICE,,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/122-085-713-827-358,Patent Application,yes,0,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A46B13/00;;A47K7/04,,0,0,,,,ACTIVE
41,ES,T3,ES 2884829 T3,178-341-697-252-292,2021-12-13,2021,ES 15786679 T,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,Dispositivo eléctrico para el cuidado de la piel,"Dispositivo eléctrico para el cuidado de la piel que comprende: una carcasa (4) con un extremo proximal ahuecado (6) y un extremo distal cerrado (8), un eje longitudinal (10) definido desde el extremo proximal (6) hasta el extremo distal (8), donde el extremo distal forma un mango (12), la carcasa (4) incluye un circuito electrónico (14) que está conectado a una batería (16), el extremo proximal (6) que define una apertura (18) orientada en un ángulo oblicuo con respecto al eje longitudinal (10), la apertura (18) que define una superficie anular en dirección hacia adentro (24); y una plataforma de soporte del cabezal (26) que define una superficie de soporte externa (28) y una superficie interna (30); un borde (32) que depende de la superficie interna (30) de la plataforma (26), el borde (32) que define una superficie anular en dirección hacia afuera (34) dimensionada para ser recibida en una relación espaciada dentro de la apertura (18) del extremo proximal (6) de la carcasa (4), el borde (32) además define una cavidad (36); al menos una estructura de soporte del accionamiento (38) se ubica en el borde (32) o en la superficie interna (28) de la plataforma (26) dentro de la cavidad (36); un amortiguador de vibraciones (40) en la forma de un collarín resistente hecho de un material elástico, el amortiguador (40) que conecta la superficie anular en dirección hacia adentro (24) de la carcasa (4) con la superficie anular en dirección hacia afuera (34) de la plataforma (26) para asegurar de forma resistente el borde (32) en la apertura (18) del extremo proximal ahuecado (6) de la carcasa (4) de modo que la superficie de soporte externa (28) de la plataforma (26) está ubicada fuera de la apertura (18); un mecanismo de vibración motorizado (42) asegurado a al menos un soporte de accionamiento (38) y conectado de manera operativa al circuito electrónico (14) y a la batería (16), el mecanismo (42) es capaz de generar vibraciones en una frecuencia de 80 Hz a 250 Hz cuando la batería (16) provee la energía, el mecanismo de vibración (42) asegurado al soporte de accionamiento (38) para hacer que la plataforma (26) vibre; y un interruptor (44) en el circuito electrónico (14) que funciona para proveer energía al mecanismo de vibración (42) desde la batería (16).",ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/178-341-697-252-292,Granted Patent,no,0,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
42,AU,A1,AU 2015/253396 A1,175-741-300-383-723,2016-11-24,2016,AU 2015/253396 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,Powered skin care device,A powered skin care device is provided with a vibration damper between a vibrating motor and a handle of the device. The vibrating motor provides vibrations in a relatively gentle frequency and the brush head is provided with relatively soft bristles.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/175-741-300-383-723,Patent Application,no,0,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A47K7/03,,0,0,,,,DISCONTINUED
43,CA,C,CA 2946874 C,182-527-088-684-874,2019-02-12,2019,CA 2946874 A,2015-04-28,US 201414264899 A;;US 2015/0027933 W,2014-04-29,POWERED SKIN CARE DEVICE,A powered skin care device is provided with a vibration damper between a vibrating motor and a handle of the device. The vibrating motor provides vibrations in a relatively gentle frequency and the brush head is provided with relatively soft bristles.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/182-527-088-684-874,Granted Patent,no,0,0,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A47K7/04;;A47K7/03,,0,0,,,,ACTIVE
44,US,B2,US 9596928 B2,044-226-466-276-892,2017-03-21,2017,US 201414264899 A,2014-04-29,US 201414264899 A,2014-04-29,Powered skin care device,A powered skin care device is provided with a vibration damper between a vibrating motor and a handle of the device. The vibrating motor provides vibrations in a relatively gentle frequency and the brush head is provided with relatively soft bristles.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,ELC MANAGEMENT LLC (2014-08-27),https://lens.org/044-226-466-276-892,Granted Patent,yes,67,16,14,14,0,A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028;;A47K7/04;;A46B13/023;;A47K7/043;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A47K7/04;;A46B13/023;;A47K7/043;;A61H7/005;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B2200/102;;A46B9/028,A46B13/02;;A46B9/06;;A46B13/00;;A47K7/04;;A61H7/00;;A61H23/02,,6,0,,,"PCT Int'l Search Report; Int'l Application No. PCT/US2015/027922; Completion Date: Jul. 17, 2015; Date of Mailing: Jan. 22, 2015.;;PCT Int'l Search Report; Int'l Application No. PCT/US2015/027933; Completion Date: Jul. 22, 2015; Date of Mailing: Jul. 22, 2015.;;PCT Int'l Search Report; Int'l Application No. PCT/US2015/027967; Completion Date: Jul. 17, 2015; Date of Mailing: Jul. 22, 2015.;;PCT Written Opin of the Int'l Searching Auth; Int'l Application No. PCT/US2015/027922; Completion Date: Jul. 17, 2015; Mailing Date: Jul. 22, 2015.;;PCT Written Opin of the Int'l Searching Auth; Int'l Application No. PCT/US2015/027933; Completion Date: Jul. 22, 2015; Mailing Date: Jul. 22, 2015.;;PCT Written Opin of the Int'l Searching Auth; Int'l Application No. PCT/US2015/027967; Completion Date: Jul. 17, 2015; Mailing Date: Jul. 22, 2015.",ACTIVE
45,US,A1,US 2015/0305486 A1,060-258-075-332-777,2015-10-29,2015,US 201414264853 A,2014-04-29,US 201414264853 A,2014-04-29,Powered Skin Care Device,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,ELC MANAGEMENT LLC (2014-08-27),https://lens.org/060-258-075-332-777,Patent Application,yes,9,9,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A46B13/00;;A46B13/02,,0,0,,,,ACTIVE
46,CA,C,CA 2946870 C,086-304-990-177-983,2019-02-05,2019,CA 2946870 A,2015-04-28,US 201414264853 A;;US 2015/0027922 W,2014-04-29,POWERED SKIN CARE DEVICE,A powered skin care device is provided with a vibrating motor that produces vibrations in a relatively gentle frequency and has a removable brush head that includes at least two types of bristles. A first group of bristles is for more gentle cleansing and a second group of bristles is for more aggressive cleansing.,ELC MAN LLC,PARDO JANET;;CECERE LOIS ANN;;OWEN THOMAS EDWARD;;WONG JENNY;;WOO-KIM CHONG WON JESSICA;;LAPOSTA RICHARD;;BELKNAP JENNY WARNER;;FISCHER HERBERT,,https://lens.org/086-304-990-177-983,Granted Patent,no,0,0,16,16,0,A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/025;;A46B2200/1006;;A61H2201/0165;;A61H2201/1685;;A61H2205/022;;A61H2205/023;;A61H7/004;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B9/06;;A46B13/008;;A46B13/023;;A47K7/043;;A46B2200/102;;A46B13/008;;A46B13/023;;A47K7/043;;A61H23/0263;;A46B7/04;;A46B9/06;;A46B2200/102;;A61H2205/022;;A61H2201/1685;;A61H2205/023;;A46B2200/1006;;A61H2205/025;;A61H2201/0165;;A61H7/004,A47K7/04;;A46B13/00,,0,0,,,,ACTIVE
47,DE,D1,DE 60220049 D1,129-692-467-341-449,2007-06-21,2007,DE 60220049 T,2002-05-13,US 30026101 P;;IB 0201800 W,2001-06-22,PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ENTHALTEND EINE FESTE DISPERSION EINES IM WASSER SCHWERLÖSLICHEN ARZNEIMITTELS UND EIN LÖSLICHKEITSTEIGERNDES POLYMER,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/129-692-467-341-449,Granted Patent,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,A61K47/38;;C07D215/42;;A61K9/08;;A61K9/14;;A61K31/40;;A61K31/47;;A61K31/497;;A61K31/498;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/42;;A61K47/44,,0,0,,,,EXPIRED
48,DE,T2,DE 60220049 T2,023-273-549-577-041,2007-08-30,2007,DE 60220049 T,2002-05-13,US 30026101 P;;IB 0201800 W,2001-06-22,"Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer","A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/023-273-549-577-041,Granted Patent,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,A61K47/38;;C07D215/42;;A61K9/08;;A61K9/14;;A61K31/40;;A61K31/47;;A61K31/497;;A61K31/498;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/42;;A61K47/44,,0,0,,,,EXPIRED
49,CA,C,CA 2448864 C,123-180-224-245-658,2008-04-22,2008,CA 2448864 A,2002-05-13,IB 0201800 W;;US 30026101 P,2001-06-22,PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OFA POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER,"A pharmaceutical composition comprises a dispersion comprising a low- solubility drug and a matrix combined with a concentration-enhancing polymer . At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,SHANKER RAVI MYSORE;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;BABCOCK WALTER CHRISTIAN;;WEST JAMES BLAIR;;NIGHTINGALE JAMES ALAN SCHRIVE;;CURATOLO WILLIAM JOHN,,https://lens.org/123-180-224-245-658,Granted Patent,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,A61K47/38;;C07D215/42;;A61K9/08;;A61K9/10;;A61K9/14;;A61K31/47;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/42;;A61K47/44,,0,0,,,,EXPIRED
50,EP,A1,EP 1401503 A1,008-075-243-388-685,2004-03-31,2004,EP 02733019 A,2002-05-13,IB 0201800 W;;US 30026101 P,2001-06-22,PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG AND A SOLUBILITY-ENHANCING POLYMER,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/008-075-243-388-685,Patent Application,yes,0,1,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,A61K47/38;;C07D215/42;;A61K9/08;;A61K9/14;;A61K31/40;;A61K31/47;;A61K31/497;;A61K31/498;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/42;;A61K47/44,,0,0,,,,EXPIRED
51,CA,A1,CA 2448864 A1,031-074-705-528-152,2003-01-03,2003,CA 2448864 A,2002-05-13,IB 0201800 W;;US 30026101 P,2001-06-22,PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OFA POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER,"A pharmaceutical composition comprises a dispersion comprising a low- solubility drug and a matrix combined with a concentration-enhancing polymer . At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,SHANKER RAVI MYSORE;;LO JULIAN BELKNAP;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;WEST JAMES BLAIR;;CURATOLO WILLIAM JOHN;;NIGHTINGALE JAMES ALAN SCHRIVE;;BABCOCK WALTER CHRISTIAN,,https://lens.org/031-074-705-528-152,Patent Application,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,C07D215/42;;A61K9/08;;A61K9/14;;A61K31/47;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/42;;A61K47/44,,0,0,,,,EXPIRED
52,AU,A1,AU 2002/304387 A1,083-616-642-095-010,2003-01-08,2003,AU 2002/304387 A,2002-05-13,US 30026101 P;;IB 0201800 W,2001-06-22,Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,WEST JAMES BLAIR;;FRIESEN DWAYNE THOMAS;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;BABCOCK WALTER CHRISTIAN;;KETNER RODNEY JAMES;;SHANKER RAVI MYSORE;;CURATOLO WILLIAM JOHN,,https://lens.org/083-616-642-095-010,Patent Application,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,C07D215/42;;A61K9/08;;A61K9/14;;A61K31/47;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/42;;A61K47/44,,0,0,,,,DISCONTINUED
53,EP,B1,EP 1401503 B1,107-956-884-208-110,2007-05-09,2007,EP 02733019 A,2002-05-13,IB 0201800 W;;US 30026101 P,2001-06-22,PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG AND A SOLUBILITY-ENHANCING POLYMER,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/107-956-884-208-110,Granted Patent,yes,5,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,A61K47/38;;C07D215/42;;A61K9/08;;A61K9/14;;A61K31/40;;A61K31/47;;A61K31/497;;A61K31/498;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/42;;A61K47/44,,0,0,,,,EXPIRED
54,WO,A1,WO 2003/000294 A1,029-367-764-182-451,2003-01-03,2003,IB 0201800 W,2002-05-13,US 30026101 P,2001-06-22,PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC;;BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/029-367-764-182-451,Patent Application,yes,5,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,C07D215/42;;A61K9/08;;A61K9/14;;A61K31/47;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/42;;A61K47/44,,0,0,,,,PATENTED
55,WO,A8,WO 2003/000294 A8,170-863-068-270-516,2003-11-06,2003,IB 0201800 W,2002-05-13,US 30026101 P,2001-06-22,PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC;;BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/170-863-068-270-516,Patent Application,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,C07D215/42;;A61K9/08;;A61K9/14;;A61K31/47;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/42;;A61K47/44,,0,0,,,,PATENTED
56,BR,A,BR 0210520 A,174-177-984-715-889,2004-06-22,2004,BR 0210520 A,2002-05-13,IB 0201800 W;;US 30026101 P,2001-06-22,Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros,"A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.",PFIZER PROD INC,BABCOCK WALTER CHRISTIAN;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;KETNER RODNEY JAMES;;LO JULIAN BELKNAP;;NIGHTINGALE JAMES ALAN SCHRIVE;;SHANKER RAVI MYSORE;;WEST JAMES BLAIR,,https://lens.org/174-177-984-715-889,Patent Application,no,0,0,19,19,0,A61K9/146;;A61P11/14;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P3/04;;A61P7/02;;A61P9/12;;A61K9/146,C07D215/42;;A61K9/08;;A61K9/14;;A61K31/47;;A61K47/02;;A61K47/10;;A61K47/12;;A61K47/14;;A61K47/18;;A61K47/20;;A61K47/24;;A61K47/26;;A61K47/30;;A61K47/32;;A61K47/34;;A61K47/36;;A61K47/38;;A61K47/42;;A61K47/44,,0,0,,,,DISCONTINUED
57,WO,A3,WO 2005/053639 A3,126-157-162-563-91X,2006-03-23,2006,IB 2004003857 W,2004-11-22,US 52731903 P,2003-12-04,CONTROLLED RELEASE MULTIPARTICULATES FORMED WITH DISSOLUTION ENHANCERS,Pharmaceutical compositions of crystalline azithromycin-containing multiparticulates having low concentrations of azithromycin ester degradants and exhibiting controlled release of the drug are achieved by inclusion of dissolution enhancers having low concentrations of acid and ester substituents.,PFIZER PROD INC;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/126-157-162-563-91X,Search Report,yes,3,0,5,5,0,A61K9/1617;;A61K9/1617,A61K9/14;;A61K9/16;;A61K9/22;;A61K31/7052,,1,0,,,"DATABASE WPI Section Ch Week 200430, Derwent World Patents Index; Class A96, AN 2004-325761, XP002350388",PENDING
58,WO,A2,WO 2005/053639 A2,159-769-392-647-726,2005-06-16,2005,IB 2004003857 W,2004-11-22,US 52731903 P,2003-12-04,CONTROLLED RELEASE MULTIPARTICULATES FORMED WITH DISSOLUTION ENHANCERS,Pharmaceutical compositions of crystalline azithromycin-containing multiparticulates having low concentrations of azithromycin ester degradants and exhibiting controlled release of the drug are achieved by inclusion of dissolution enhancers having low concentrations of acid and ester substituents.,PFIZER PROD INC;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/159-769-392-647-726,Patent Application,yes,0,2,5,5,0,A61K9/1617;;A61K9/1617,A61K9/14;;A61K9/16;;A61K9/22;;A61K31/7052,,0,0,,,,PENDING
59,TW,A,TW 200528139 A,173-216-950-737-29X,2005-09-01,2005,TW 93137411 A,2004-12-03,US 52731903 P,2003-12-04,Controlled release multiparticulates formed with dissolution enhancers,Pharmaceutical compositions of crystalline azithromycin-containing multiparticulates having low concentrations of azithromycin ester degradants and exhibiting controlled release of the drug are achieved by inclusion of dissolution enhancers having low concentrations of acid and ester substituents.,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/173-216-950-737-29X,Patent of Addition,no,0,0,5,5,0,A61K9/1617;;A61K9/1617,A61K9/16;;A61K9/14;;A61K9/22;;A61K31/7048;;A61K31/7052,,0,0,,,,PENDING
60,WO,A8,WO 2005/053652 A8,183-070-469-918-522,2005-08-04,2005,IB 2004003808 W,2004-11-22,US 52732903 P,2003-12-04,MULTIPARTICULATE CRYSTALLINE DRUG COMPOSITIONS CONTAINING A POLOXAMER AND A GLYCERIDE,"A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt% of the drug in the multiparticulate is crystalline.",PFIZER PROD INC;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT M;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;RAY RODERICK JACK;;WEST JAMES BLAIR,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT M;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/183-070-469-918-522,Patent Application,no,0,0,4,4,0,A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K31/4422;;A61K31/7032;;A61K31/7032;;A61K9/1635;;A61K9/1617;;A61K9/1641;;A61K31/4422;;A61K9/1694,A61K9/16;;A61K31/00;;A61K31/4422;;A61K31/7032,,0,0,,,,PENDING
61,CA,A1,CA 2591923 A1,152-213-429-132-737,2006-06-29,2006,CA 2591923 A,2005-12-09,US 63828704 P;;IB 2005003764 W,2004-12-21,ENTERIC COATED AZITHROMYCIN MULTIPARTICULATES,,PFIZER PROD INC,LYON DAVID KEITH;;LO JULIAN BELKNAP;;APPEL LEAH ELIZABETH;;HERBIG SCOTT MAX;;CURATOLO WILLIAM JOHN;;LEMOTT STEVEN ROSS;;FRIESEN DWAYNE THOMAS;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/152-213-429-132-737,Patent Application,no,0,0,5,5,0,A61K9/5073;;A61K9/5073;;A61K9/0095;;A61K9/0095;;A61K9/1617;;A61K9/1617;;A61K9/5026;;A61K9/5026;;A61K9/5042;;A61K9/5042;;A61P31/04,A61K9/16,,0,0,,,,DISCONTINUED
62,EP,A1,EP 1830815 A1,059-716-195-888-438,2007-09-12,2007,EP 05811088 A,2005-12-09,IB 2005003764 W;;US 63828704 P,2004-12-21,ENTERIC COATED AZITHROMYCIN MULTIPARTICULATES,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/059-716-195-888-438,Patent Application,yes,0,0,5,5,0,A61K9/5073;;A61K9/5073;;A61K9/0095;;A61K9/0095;;A61K9/1617;;A61K9/1617;;A61K9/5026;;A61K9/5026;;A61K9/5042;;A61K9/5042;;A61P31/04,A61K9/16,,1,0,,,See references of WO 2006067576A1,DISCONTINUED
63,WO,A1,WO 2006/067576 A1,087-795-725-173-047,2006-06-29,2006,IB 2005003764 W,2005-12-09,US 63828704 P,2004-12-21,ENTERIC COATED AZITHROMYCIN MULTIPARTICULATES,A pharmaceutical composition is disclosed which comprises multiparticulates wherein said multiparticulates further comprise an azithromycin core and an enteric coating disposed upon said azithromycin core.,PFIZER PROD INC;;APPEL LEAH ELIZABETH;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,APPEL LEAH ELIZABETH;;CURATOLO WILLIAM JOHN;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/087-795-725-173-047,Patent Application,yes,6,4,5,5,0,A61K9/5073;;A61K9/5073;;A61K9/0095;;A61K9/0095;;A61K9/1617;;A61K9/1617;;A61K9/5026;;A61K9/5026;;A61K9/5042;;A61K9/5042;;A61P31/04,A61K9/16,,1,0,,,"DATABASE WPI Section Ch Week 200562, Derwent World Patents Index; Class A96, AN 2005-598311, XP002372041",PENDING
64,WO,A1,WO 2005/053652 A1,175-362-771-583-326,2005-06-16,2005,IB 2004003808 W,2004-11-22,US 52732903 P,2003-12-04,MULTIPARTICULATE CRYSTALLINE DRUG COMPOSITIONS CONTAINING A POLOXAMER AND A GLYCERIDE,"A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt% of the drug in the multiparticulate is crystalline.",PFIZER PROD INC;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT M;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;RAY RODERICK JACK;;WEST JAMES BLAIR,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT M;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/175-362-771-583-326,Patent Application,yes,2,1,4,4,0,A61K9/1617;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K31/4422;;A61K31/7032;;A61K31/7032;;A61K9/1635;;A61K9/1617;;A61K9/1641;;A61K31/4422;;A61K9/1694,A61K9/16;;A61K31/00;;A61K31/4422;;A61K31/7032,,4,4,032-211-108-473-725;;074-387-181-329-482;;016-340-877-692-261;;018-676-942-833-481,10.1016/s0378-5173(99)00076-9;;10361164;;12927387;;10.1016/s0378-5173(03)00336-3;;10.1016/s0378-5173(00)00325-2;;10704799;;2014208;;10.1023/a:1015874121860,"RODRIGUEZ L ET AL: ""Description and preliminary evaluation of a new ultrasonic atomizer for spray-congealing processes."", INTERNATIONAL JOURNAL OF PHARMACEUTICS. 25 JUN 1999, vol. 183, no. 2, 25 June 1999 (1999-06-25), pages 133 - 143, XP002325411, ISSN: 0378-5173;;SAVOLAINEN MARJA ET AL: ""Evaluation of polar lipid-hydrophilic polymer microparticles."", INTERNATIONAL JOURNAL OF PHARMACEUTICS. 27 AUG 2003, vol. 262, no. 1-2, 27 August 2003 (2003-08-27), pages 47 - 62, XP002325412, ISSN: 0378-5173;;EMÅS M ET AL: ""Methods of studying aging and stabilization of spray-congealed solid dispersions with carnauba wax. 1. Microcalorimetric investigation."", INTERNATIONAL JOURNAL OF PHARMACEUTICS. 20 MAR 2000, vol. 197, no. 1-2, 20 March 2000 (2000-03-20), pages 117 - 127, XP002325413, ISSN: 0378-5173;;ELDEM T ET AL: ""Optimization of spray-dried and -congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy"", PHARMACEUTICAL RESEARCH 1991 UNITED STATES, vol. 8, no. 1, 1991, pages 47 - 54, XP009046625, ISSN: 0724-8741",PENDING
65,DE,D1,DE 602004016444 D1,174-949-527-207-798,2008-10-23,2008,DE 602004016444 T,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin enthaltende pharmazeutische Zusammensetzungen mit verringerten Nebenwirkungen,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/174-949-527-207-798,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
66,EA,B1,EA 010110 B1,195-815-374-721-072,2008-06-30,2008,EA 200401216 A,2004-05-14,US 52708403 P;;US 76334004 A;;IB 2004001654 W,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINACH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/195-815-374-721-072,Granted Patent,no,6,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/00;;A61P31/04,,0,0,,,,ACTIVE
67,OA,A,OA 12858 A,000-997-801-733-528,2006-09-15,2006,OA 1200400253 A,2004-05-14,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin dosage forms with reduced side effects.,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEIT;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/000-997-801-733-528,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K31/7048;;C07H17/00;;A61K9/00;;A61K9/14;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
68,GE,B,GE P20074056 B,031-882-638-930-680,2007-03-12,2007,GE AU2004008414 A,2004-05-14,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprises alkalizing agent and an azithromycin multiparticulate compri¬sing azithromycin and glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate and a po¬loxamer.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/031-882-638-930-680,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
69,AU,B2,AU 2004/216676 B2,067-778-686-825-697,2011-06-16,2011,AU 2004/216676 A,2004-05-14,US 76334004 A;;US 52708403 P;;IB 2004001654 W,2003-12-04,Azithromycin dosage forms with reduced side effects,,PFIZER PROD INC,MCCRAY SCOTT BALDWIN;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;LO JULIAN BELKNAP;;APPEL LEAH ELIZABETH;;WEST JAMES BLAIR;;HERBIG SCOTT MAX;;CREW MARSHALL DAVID;;LYON DAVID KEITH;;THOMBRE AVINASH GOVIND,,https://lens.org/067-778-686-825-697,Granted Patent,no,0,0,11,67,0,,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K38/00;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
70,CN,B,CN 1697648 B,195-803-030-157-326,2010-06-23,2010,CN 200480000209 A,2004-05-14,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin dosage forms with reduced side effects,"The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.",PFIZER PROD INC,KEITH LYON DAVID;;THOMAS FIESEN DWAYNE;;BELKNAP LO JULIAN;;BLAIR WEST JAMES;;MAX HERBIG SCOTT;;ELIZABETH APPEL LEAH;;GOVIND THOMBRE AVINASH;;ARTHUR HAGEN TIMOTHY;;BALDWIN MCCRAY SCOTT;;DAVID CREW MARSHALL,,https://lens.org/195-803-030-157-326,Granted Patent,no,0,0,11,67,0,,A61K47/02;;A61K9/16;;A61K31/70;;A61K38/00;;A61K47/14;;A61K47/34;;A61P31/04,,0,0,,,,ACTIVE
71,JP,A,JP 2005162733 A,194-476-491-355-286,2005-06-23,2005,JP 2004228455 A,2004-08-04,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN PREPARATION FORM EXHIBITING ONLY FEW ADVERSE EFFECT,"<P>PROBLEM TO BE SOLVED: To provide an azithromycin preparation form having a bioavailability resembling to that of an instantaneous releasing type azithromycin of the same dose and less gastrointestinal adverse effects. <P>SOLUTION: This azithromycin oral preparation contains an effective amount of an alkalizing agent and azithromycin multiple particles. <P>COPYRIGHT: (C)2005,JPO&NCIPI",PFIZER PROD INC,HAGEN TIMOTHY A;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH E;;CREW MARSHALL D;;DWAYNE THOMAS FREESEN;;LYON DAVID K;;MCCRAY SCOTT B;;WEST JAMES B,,https://lens.org/194-476-491-355-286,Patent Application,no,11,11,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
72,MA,A1,MA 27848 A1,040-521-108-438-296,2006-04-03,2006,MA 28638 A,2005-12-08,US 52708403 P;;US 76334004 A,2003-12-04,FORMES POSOLOGIQUES D'AZITHROMYCINE A EFFETS SECONDAIRES REDUITS.,"DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 4 Décembre 2003 60/527,084 US 23 Janvier 2004 10/763,340 Voir en annexe le titre de l'invention et le texte de l'abrégé Formes posologiques d'azithromycine à effets secondaires réduits Une forme posologique orale comprenant de l??azithromycine et une quantité efficace d'un agent alcalinisant. De préférence, ladite forme posologique orale comprend une quantité efficace d'un agent alcalinisant et une forme en particules multiples d1azithromycine, ladite forme en particules multiples comprenant de l??azithromycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Habituellement, la forme posologique orale comprend n'importe quel moyen d'administration orale convenable tel qu'une poudre pour suspension orale, un paquet ou sachet de dose unitaire, un comprimé ou une capsule. Il est révélé en outre une suspension orale comprenant de l'azithromycine, une quantité efficace d'un agent alcalinisant et un véhicule. De préférence, l??azithromycine est une forme en particules multiples dans laquelle lesdites particules multiples comprennent de l'azithro-mycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Il est révélé également une méthode pour réduire les effets secondaires gastro-intestinaux, associés à l'administration d1azithromycine à un mammifère, comprenant l'administration de manière contigue d'azithromycine et d'une quantité efficace d'un agent alcalinisant audit mammifère, la fréquence des effets secondaires gastro-intestinaux étant inférieure à celle constatée en administrant une dose égale d'azithromycine sans ledit agent alcalinisant. Il est révélé en outre une méthode pour le traitement d'une infection par des bactéries ou des protozoaires chez un mammifère nécessitant un tel traitement, comprenant l'administration de manière contigue audit mammifère d'une dose unique d'une forme posologique orale, ladite forme posologique orale comprenant del??azithromycine et une quantité efficace d'un agent alcalinisant. Il est révélé en outre une forme en particules multiples d'azithromycine comprenant del??azithromycine, un agent tensio-actif et un support pharmaceutiquement acceptable.",PFIZER PROD INC,THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;HAGEN TIMOTHY ARTHUR,,https://lens.org/040-521-108-438-296,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
73,AP,A,AP 2218 A,127-682-751-367-310,2011-04-20,2011,AP 2004003145 A,2004-05-14,US 52708403 P;;IB 2004001654 W,2003-12-04,Azithromycin dosage forms with reduced side effects,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/127-682-751-367-310,Granted Patent,no,3,0,11,67,0,,A61K9/00;;A61K9/16;;A61K38/00;;C07H17/00,,0,0,,,,ACTIVE
74,HR,A2,HR P20040865 A2,122-470-919-853-827,2006-02-28,2006,HR P20040865 A,2004-09-20,US 52708403 P;;US 76334004 A;;IB 2004001654 W,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"Oralni oblik doziranja, koji sadrži azitromicin idjelotvornu količinu alkalizirajućeg sredstva. Pomogućnosti, navedeni oralni oblik doziranja sadrži djelotvornu količinu alkalizirajućeg sredstva i multipartikulate azitromicina, pri čemu navedeni multipartikulati sadrže azitromicin, smjesu gliceril-monobehenata, gliceril-dibehenata i gliceril-tribehenata, te poloksamer. Tipično, oralni oblik doziranja sadrži bilo koje pogodno oralno dozirano sredstvo, poput praška za oralnu suspenziju, pakiranja jedinica doze ili kašete, tablete ili kapsule. Dodatno je opisana oralna suspenzija koja sadrži azitromicin, djelotvornu količinu alkalizirajućeg sredstva i vehikulum. Po mogućnosti, azitromicin jeu obliku multipartikulata, pri čemu navedeni multipartikulati sadrže azitromicin, smjesu gliceril-monobehenata, gliceril-dibehenata i gliceril-tribehenata i poloksamer. Također je opisan postupak smanjenja gastrointestinalnih nuspojava, povezanih s primjenom azitromicina na sisavcu, koji se sastojiu zajedničkoj primjeni azitromicina i djelotvornekoličine alkalizirajućeg sredstva na navedenom sisavcu, pri čemu je učestalost gastrointestinalnih nuspojava manja nego učestalost prilikom primjene iste doze azitromicina bez navedenog alkalizirajućeg sredstva. Dalje je opisan postupak liječenja bakterijske ili protozoalne infekcije kod sisavca kojem je to potrebno, koji se sastoji u zajedničkoj primjeni na navedenom sisavcu pojedinačne doze oralnog oblika doziranja, pri čemu navedeni oralni oblik doziranja sadrži azitromicin i djelotvornu količinu alkalizirajućeg sredstva. Dodatno su opisanimultipartikulati azitromicina koji sadrže azitromicin, surfaktant, te farmaceutski prihvatljivu podlogu.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/122-470-919-853-827,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,DISCONTINUED
75,PL,T3,PL 1537859 T3,074-471-796-702-951,2009-01-30,2009,PL 04252643 T,2004-05-06,US 52708403 P;;US 76334004 A;;EP 04252643 A,2003-12-04,Azithromycin dosage forms with reduced side effects,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/074-471-796-702-951,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,PENDING
76,NL,C2,NL 1026315 C2,098-447-571-043-132,2006-01-24,2006,NL 1026315 A,2004-06-02,US 76334004 A;;US 52708403 P,2003-12-04,Azithromycinedoseringsvormen met verminderde bijwerkingen.,,PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/098-447-571-043-132,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K47/00;;C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,INACTIVE
77,JP,A,JP 2010132700 A,167-331-587-601-713,2010-06-17,2010,JP 2010044743 A,2010-03-01,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORM WITH REDUCED SIDE EFFECT,"<P>PROBLEM TO BE SOLVED: To provide an azithromycin dosage form which has bioavailability analogical to an instantly dischargeable azithromycin with the same dose and has gastrointestinal side effect smaller than the bioavailability. <P>SOLUTION: The azithromycin dosage form includes azithromycin multiparticles and an effective amount of an alkalizing agent. Preferably, the alkalizing agent includes an aluminum salt, a magnesium salt, a calcium salt, a bicarbonate, a phosphate, a metal hydroxide, a metal oxide, N-methylglucamine, arginine, an arginine salt, an amine, or a combination thereof. <P>COPYRIGHT: (C)2010,JPO&INPIT",PFIZER PROD INC,HAGEN TIMOTHY A;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH E;;CREW MARSHALL D;;DWAYNE THOMAS FREESEN;;LYON DAVID K;;MCCRAY SCOTT B;;WEST JAMES B,,https://lens.org/167-331-587-601-713,Patent Application,no,10,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K31/7052;;C07H17/00;;A61K9/00;;A61K9/14;;A61K9/16;;A61K9/20;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/34;;A61K47/44;;A61P31/04;;A61P33/00,,0,0,,,,PENDING
78,DK,T3,DK 1537859 T3,015-258-269-556-320,2008-11-17,2008,DK 04252643 T,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycindoseringsformer med reducerede bivirkninger,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/015-258-269-556-320,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
79,CA,A1,CA 2467611 A1,059-923-294-697-399,2005-06-04,2005,CA 2467611 A,2004-05-18,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, th e oral dosage form includes any suitable oral dosing means such as a powder for ora l suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, a n effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to sa id mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mamma l a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.</SDOA B>",PFIZER PROD INC,LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;HAGEN TIMOTHY ARTHUR;;LO JULIAN BELKNAP;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;WEST JAMES BLAIR;;CREW MARSHALL DAVID,,https://lens.org/059-923-294-697-399,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
80,NO,L,NO 20043903 L,076-580-411-826-271,2004-11-09,2004,NO 20043903 A,2004-09-17,US 52708403 P;;US 76334004 A;;IB 2004001654 W,2003-12-04,Azitromycindoseringsform med reduserte bivirkninger,,PFIZER PROD INC,MCCRAY SCOTT BALDWIN;;LYON DAVID KEITH;;WEST JAMES BLAIR;;THOMBRE AVINASH GOVIND;;HERBIG SCOTT MAX;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTY ARTHUR;;LO JULIAN BELKNAP,,https://lens.org/076-580-411-826-271,Abstract,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,DISCONTINUED
81,IS,B,IS 2672 B,080-142-640-991-267,2010-09-15,2010,IS 7464 A,2004-09-20,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/080-142-640-991-267,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/00;;C07H17/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
82,KR,A,KR 20060033851 A,094-821-431-552-287,2006-04-20,2006,KR 20047016213 A,2004-10-11,US 76334004 A;;US 52708403 P,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/094-821-431-552-287,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K31/7052;;C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
83,RS,A,RS 84704 A,111-850-312-513-071,2007-02-05,2007,YU P84704 A,2004-05-14,US 52708403 P;;US 76334004 A;;IB 2004001654 W,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/111-850-312-513-071,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,PENDING
84,HK,B,HK 1080367 B,149-348-761-338-251,2010-11-05,2010,HK 06100226 A,2006-01-05,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,,PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/149-348-761-338-251,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P/;;A61P31/04,,0,0,,,,ACTIVE
85,BR,B1,BR PI0403935 B1,005-060-420-607-076,2018-02-06,2018,BR PI0403935 A,2004-05-14,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,formas de dosagem de azitromicina com efeitos colaterais reduzidos,"""formas de dosagem de azitromicina com efeitos colaterais reduzidos"". uma forma de dosagem oral compreendendo azitromicina e um quantidade eficaz de um agente de alcalinização. preferivelmente, a referida forma de dosagem oral compreende uma quantidade eficaz de um agente de alcalinização e um multiparticulado de azitromicina onde o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. tipicamente, a forma de dosagem oral inclui quaisquer métodos de dosagem oral adequados tal como um pó para suspensão oral, uma embalagem ou sachê de dose única, um comprimido ou uma cápsula. adicionalmente é descrita uma suspensão oral compreendendo azitromicina, uma quantidade eficaz de um agente de alcalinização e um veículo. preferivelmente, a azitromicina é em forma de multiparticulado em que o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. é também descrito um método para reduzir efeitos colaterais gastrointestinais, associados com administração de azitromicina a um mamífero, compreendendo administrar contiguamente azitromicina e uma quantidade eficaz de agente de alcalinização ao referido mamífero em que a freqüência de efeitos colaterais gastrointestinais é menor do que aquela experimentada administrando-se uma dose igual de azitromicina sem o referido agente de alcalinização. além disso é descrito um método de tratar uma infecção bacteriana ou protozoária em um mamífero em necessidade deste compreendendo administrar contiguamente ao referido mamífero uma dose única de uma forma de dosagem oral em que a referida forma de dosagem oral compreende azitromicina e uma quantidade eficaz de um agente de alcalinização. adicionalmente são descritos multiparticulados de azitromicina compreendendo azitromicina, um tensoativo; e um veículo farmaceuticamente aceitável.",PFIZER PROD INC,AVINASH GOVIND THOMBRE;;DAVID KEITH LYON;;DWAYNE THOMAS FRIESEN;;JAMES BLAIR WEST;;JULIAN BELKNAP LO;;LEAH ELISABETH APPEL;;MARSHALL DAVID CREW;;SCOTT BALDWIN MCCRAY;;SCOTT MAX HERBIG;;TIMOTHY ARTHUR HAGEN,,https://lens.org/005-060-420-607-076,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/00;;A61P31/04,,0,0,,,,ACTIVE
86,BR,B8,BR PI0403935 B8,049-387-217-526-490,2021-05-25,2021,BR PI0403935 A,2004-05-14,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,formas de dosagem de azitromicina com efeitos colaterais reduzidos,"""formas de dosagem de azitromicina com efeitos colaterais reduzidos"". uma forma de dosagem oral compreendendo azitromicina e um quantidade eficaz de um agente de alcalinização. preferivelmente, a referida forma de dosagem oral compreende uma quantidade eficaz de um agente de alcalinização e um multiparticulado de azitromicina onde o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. tipicamente, a forma de dosagem oral inclui quaisquer métodos de dosagem oral adequados tal como um pó para suspensão oral, uma embalagem ou sachê de dose única, um comprimido ou uma cápsula. adicionalmente é descrita uma suspensão oral compreendendo azitromicina, uma quantidade eficaz de um agente de alcalinização e um veículo. preferivelmente, a azitromicina é em forma de multiparticulado em que o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. é também descrito um método para reduzir efeitos colaterais gastrointestinais, associados com administração de azitromicina a um mamífero, compreendendo administrar contiguamente azitromicina e uma quantidade eficaz de agente de alcalinização ao referido mamífero em que a freqüência de efeitos colaterais gastrointestinais é menor do que aquela experimentada administrando-se uma dose igual de azitromicina sem o referido agente de alcalinização. além disso é descrito um método de tratar uma infecção bacteriana ou protozoária em um mamífero em necessidade deste compreendendo administrar contiguamente ao referido mamífero uma dose única de uma forma de dosagem oral em que a referida forma de dosagem oral compreende azitromicina e uma quantidade eficaz de um agente de alcalinização. adicionalmente são descritos multiparticulados de azitromicina compreendendo azitromicina, um tensoativo; e um veículo farmaceuticamente aceitável.",PFIZER PROD INC,SCOTT MAX HERBIG;;AVINASH GOVIND THOMBRE;;DAVID KEITH LYON;;DWAYNE THOMAS FRIESEN;;JAMES BLAIR WEST;;JULIAN BELKNAP LO;;LEAH ELISABETH APPEL;;MARSHALL DAVID CREW;;SCOTT BALDWIN MCCRAY;;TIMOTHY ARTHUR HAGEN,,https://lens.org/049-387-217-526-490,Amended Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/00;;A61P31/04,,0,0,,,,ACTIVE
87,IS,A,IS 7464 A,063-396-057-135-811,2005-06-05,2005,IS 7464 A,2004-09-20,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir,,PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/063-396-057-135-811,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
88,TW,B,TW I351969 B,150-279-382-449-292,2011-11-11,2011,TW 93116207 A,2004-06-04,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin dosage forms with reduced side effect,,PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/150-279-382-449-292,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
89,CR,A,CR 7500 A,007-649-495-357-125,2007-09-03,2007,CR 7500 A,2004-09-29,US 52708403 P;;US 76334004 A,2003-12-04,FORMAS DE DOSIFICACION DE AZITROMICIDA CON EFECTOS SECUNDARIOS REDUCIDOS,"Una forma de dosificacion oral que comprende azitromicina y una cantidad eficaz de un agente alcalinizante. Preferiblemente, dicha forma de dosificacion oral comprende una cantidad eficaz de un agente alcanizante y un multiparticulado de azitromicina en el que dicho multiparticulado comprende azitromicina, una mezcla de monobehenato de glicerilo, dibehenato de glicerilo y tribehenato de glicerilo y un poloxamero. Tipicamente, la forma de dosificacion oral incluye cualquier medio deadministracion oral adecuado tal como un polvo para suspension oral, un envase o sobrecito de dosis unitaria, un comprimido o una capsula.",PFIZER PROD INC,TIMOTHY ARTHUR HAGEN;;SCOTT MAX HERBIG;;JULIAN BELKNAP LO;;AVINASH GOVIND THOMBRE;;LEAH ELIZABETH APPEL;;MARSHALL DAVID CREW;;DWAYNE THOMAS FRIESEN;;DAVID KEITH LYON;;SCOTT BALDWIN MACRAY;;JAMES BLAIR WEST,,https://lens.org/007-649-495-357-125,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/00;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,PENDING
90,NL,A1,NL 1026315 A1,013-568-580-350-377,2005-06-07,2005,NL 1026315 A,2004-06-02,US 76334004 A;;US 52708403 P,2003-12-04,Azithromycinedoseringsvormen met verminderde bijwerkingen.,,PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/013-568-580-350-377,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,INACTIVE
91,WO,A8,WO 2005/053650 A8,054-493-992-517-819,2005-12-01,2005,IB 2004001654 W,2004-05-14,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/054-493-992-517-819,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,PENDING
92,CA,C,CA 2467611 C,058-516-705-964-320,2010-03-30,2010,CA 2467611 A,2004-05-18,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/058-516-705-964-320,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K31/7052;;C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04;;A61P33/02,,0,0,,,,ACTIVE
93,WO,A1,WO 2005/053650 A1,166-217-813-024-016,2005-06-16,2005,IB 2004001654 W,2004-05-14,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/166-217-813-024-016,Patent Application,yes,6,14,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,PENDING
94,HK,A1,HK 1080367 A1,000-837-357-266-94X,2006-04-28,2006,HK 06100226 A,2006-01-05,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,,PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/000-837-357-266-94X,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P/;;A61P31/04,,0,0,,,,ACTIVE
95,TW,A,TW 200518784 A,159-580-278-769-317,2005-06-16,2005,TW 93116207 A,2004-06-04,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin dosage forms with reduced side effects,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/159-580-278-769-317,Patent of Addition,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7048;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
96,CY,T1,CY 1108486 T1,002-583-271-034-713,2014-04-09,2014,CY 081101264 T,2008-11-06,EP 04252643 A;;US 52708403 P;;US 76334004 A,2003-12-04,ΜΟΡΦΕΣ ΔΟΣΟΛΟΓΙΑΣ ΑΖΙΘΡΟΜΥΚΙΝΗΣ ΜΕ ΜΕΙΩΜΕΝΕΣ ΠΑΡΕΝΕΡΓΕΙΕΣ,"Μία μορφή δοσολογίας δια του στόματος περιλαμβάνουσα αζιθρομυκίνη και μία αποτελεσματική ποσότητα ενός παράγοντα αλκαλοποιήσεως. Κατά προτίμηση, η εν λόγω μορφή δοσολογίας δια του στόματος περιλαμβάνει μία αποτελεσματική ποσότητα ενός παράγοντα αλκαλοποιήσεως και μία πολυσωματιδιακή αζιθρομυκίνη όπου τα εν λόγω πολυσωματίδια περιλαμβάνουν αζιθρομυκίνη, ένα μίγμα μονοβεχενικού γλυκερυλίου, διβεχενικού γλυκερυλίου και τριβεχενικού γλυκερυλίου και ένα πολοξαμερές. Τυπικά, η μορφή δοσολογίας δια του στόματος περιλαμβάνει οποιοδήποτε κατάλληλο μέσο χορηγήσεως δια του στόματος όπως κόνη για στοματικό εναιώρημα, ένα πακέτο ή φακελίσκο μοναδιαίας δόσεως, ένα δισκίο ή μία κάψουλα. Αποκαλύπτεται επί πλέον ένα στοματικό εναιώρημα περιλαμβάνον αζιθρομυκίνη, μία αποτελεσματική ποσότητα ενός παράγοντα αλκαλοποιήσεως και ένα όχημα. Κατά προτίμηση, η αζιθρομυκίνη είναι σε πολυσωματιδιακή μορφή όπου η εν λόγω πολυσωματιδιακή σύνθεση περιλαμβάνει αζιθρομυκίνη, ένα μίγμα μονοβεχενικού γλυκερυλίου, διβεχενικού γλυκερυλίου και τριβεχενικού γλυκερυλίου και ένα πολοξαμερές. Αποκαλύπτεται επίσης μία μέθοδος μειώσεως των γαστρεντερικών παρενεργειών που συνδέονται με τη χορήγηση αζιθρομυκίνης σε ένα θηλαστικό, περιλαμβάνουσα τη γειτονική χορήγηση αζιθρομυκίνης και μίας αποτελεσματικής ποσότητας ενός παράγοντα αλκαλοποιήσεως στο εν λόγω θηλαστικό όπου η συχνότητα των γαστρεντερικών παρενεργειών είναι χαμηλότερη από εκείνη που παρουσιάζεται δια χορηγήσεως μίας ίσης δόσεως αζιθρομυκίνης χωρίς τον εν λόγω παράγοντα αλκαλοποιήσεως. Αποκαλύπτεται περαιτέρω μία μέθοδος αγωγής μίας βακτηριακής ή πρωτοζωικής λοιμώξεως",PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/002-583-271-034-713,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
97,PT,E,PT 1537859 E,054-885-766-595-504,2008-11-18,2008,PT 04252643 T,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,,PFIZER PROD INC,THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/054-885-766-595-504,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
98,UA,C2,UA 78793 C2,127-698-355-131-476,2007-04-25,2007,UA 20041210181 A,2004-05-14,US 52708403 P;;IB 2004001654 W,2003-12-04,ORAL DOSAGE FORM OF AZITROMYCIN WITH DECREASED SIDE EFFECTS,"The invention relates to the oral dosage form containing Azitromycin and the effective amount of alkalization agent. Preferably, the said oral dosage form comprises the effective amount of alkalization agent and multiparticles of Azitromycin containing Azitromycin and the mixture of glycerylmonobechenate, glyceryldibechenate, glyceryltribechenate, and poloxamer. Also disclosed are the method for decreasing the gastrointestinal side effects and the method for treating bacterial or protozoal infection in the mammals using the said oral dosage form.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON KEITH DAVID;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/127-698-355-131-476,Limited Patent,no,0,0,11,67,0,,A61K9/14;;A61K9/16;;A61K31/704;;A61K38/00;;A61P31/00,,0,0,,,,EXPIRED
99,AU,A1,AU 2004/216676 A1,099-526-910-495-806,2005-06-23,2005,AU 2004/216676 A,2004-05-14,US 76334004 A;;US 52708403 P;;IB 2004001654 W,2003-12-04,Azithromycin dosage forms with reduced side effects,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;THOMBRE AVINASH GOVIND;;LO JULIAN BELKNAP;;HERBIG SCOTT MAX;;HAGEN TIMOTHY ARTHUR;;WEST JAMES BLAIR;;MCCRAY SCOTT BALDWIN;;LYON DAVID KEITH;;FRIESEN DWAYNE THOMAS;;CREW MARSHALL DAVID,,https://lens.org/099-526-910-495-806,Patent Application,no,0,0,11,67,0,,A61K9/16;;A61K38/00,,0,0,,,,ACTIVE
100,NZ,A,NZ 535464 A,108-516-515-400-315,2009-03-31,2009,NZ 53546404 A,2004-05-14,US 52708403 P;;US 76334004 A;;IB 2004001654 W,2003-12-04,Azithromycin dosage forms with reduced side effects,"Disclosed is an oral dosage form comprising: a) an effective amount of an alkalizing agent; and b) multiparticulates comprising i) azithromycin; ii) a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate; and iii) a poloxamer.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;WEST JAMES BLAIR;;MCCRAY SCOTT BALDWIN,,https://lens.org/108-516-515-400-315,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,PENDING
101,ZA,B,ZA 200408075 B,181-238-890-928-728,2007-01-31,2007,ZA 200408075 A,2004-10-06,US 52708403 P,2003-12-04,Azithromycin dosage forms with reduced side effects,,PFIZER PROD INC,ARTHUR HAGEN TIMOTHY;;BELKNAP LO JULIAN;;ELIZABETH APPEL LEAH;;THOMAS FRIESEN DWAYNE;;BALDWIN MCCRAY SCOTT;;MAX HERBIG SCOTT;;GOVIND THOMBRE AVINASH;;DAVID CREW MARSHALL;;KEITH LYON DAVID;;BLAIR WEST JAMES,,https://lens.org/181-238-890-928-728,Granted Patent,no,0,0,11,67,0,,A61K/;;A61K9/16;;A61K38/00,,0,0,,,,ACTIVE
102,EP,A2,EP 1537859 A2,182-100-570-753-249,2005-06-08,2005,EP 04252643 A,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin dosage forms with reduced side effects,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/182-100-570-753-249,Patent Application,yes,0,7,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
103,PL,A1,PL 379984 A1,182-797-621-082-522,2006-11-27,2006,PL 37998404 A,2004-05-14,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS,,PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/182-797-621-082-522,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,DISCONTINUED
104,TN,A1,TN SN05319 A1,066-951-711-188-504,2007-07-10,2007,TN SN05319 A,2005-12-14,IB 2004001654 W;;US 52708403 P,2003-12-04,FORMES POSOLOGIQUES D'AZITHROMYCINE A EFFETS SECONDAIRES REDUITS,"Une forme posologique orale comprenant de l'azithromycine et une quantité efficace d'un agent alcanilisant. De préférence, ladite forme posologique orale comprend une quantité efficace d'un agent alcalinisant et une forme en particules multiples d'azithromycine, ladite forme en particules multiples comprenant de l'azithromycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Habituellement, la forme posologique orale comprend n'importe quel moyen d'administration orale convenable tel qu'une poudre pour suspension orale, un paquet ou sachet de dose unitaire, un comprimé ou une capsule. Il est révélé en outre une suspension orale comprenant de l'azithromycine, une quantité efficace d'un agent alcalinisant et un véhicule. De préférence, l'azithromycine est une forme en particules multiples dans laquelle lesdites particules multiples comprennent de l'azithromycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Il est révélé également une méthode pour réduire les effets secondaires gastro-intestinaux, associés à l'administration d'azithromycine à un mammifère, comprenant l'administration de manière contiguë d'azithromycine et d'une quantité efficace d'un agent alcalinisant audit mammifère, la fréquence des effets secondaires gastro-intestinaux étant inférieur à celle constatée en administrant une dose égale d'azithromycine sans ledit agent alcalinisant. Il est révélé en outre une méthode pour le traitement d'une infection par des bactéries ou des protozoaires chez un mammifère nécessitant un tel traitement, comprenant l'administration de manière contiguë audit mammifère d'une dose unique d'une forme posologique orale, ladite forme posologique orale, comprenant de l'azithromycine et une quantité efficace d'un agent alcalinisant. Il est révélé en outre une forme en particules multiples d'azithromycine comprenant de l'azithromycine, un agent tensio-actif et un support pharmaceutiquement acceptable.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;7FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/066-951-711-188-504,Patent Application,no,0,0,11,67,0,,A61K9/16;;A61K38/00,,0,0,,,,PENDING
105,DO,A,DO P2004000994 A,088-905-283-519-725,2005-06-30,2005,DO 2004000994 A,2004-09-09,US 52708403 P;;US 76334004 A,2003-12-04,DERIVADOS DE INDANO HETEROCICLICOS SUSTITUIDOS Y COMPUESTOS RELACIONADOS PARA EL TRATAMIENTO DE LA ESQUIZOFRENIA.,"UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE. PREFERIBLEMENTE, DICHA FORMA DE DOSIFICACION ORAL COMPRENDE UNA CANTIDAD EFICAZ DE UN AGENTE ALCALIRIIZANTE Y UN MULTIPARTICULADO DE AZITROMICINA EN EL QUE DICHO MULTIPARTICULADO COMPRENDE AZITROMICINA, UNA MEZCLA DE MONOBEHENATO DE GLICERILO, DIBEHENATO DE GLICERILO Y TRIBEHENATO DE GLICERHO Y UN POLOXAMERO. TIPICAMENTE, LA FORMA DE DOSIFICACION ORAL INCLUYE CUALQUIER MEDIO DE ADMINISTRACION ORAL ADECUADO TAL COMO UN POLVO PARA SUSPENSION ORAL, UN ENVASE O SOBRECITO DE DOSIS UNITARIA, UN COMPRIMIDO O UNA CAPSULA. EMAS SE DESCRIBE UNA SUSPENSION ORAL QUE COMPRENDE AZITROMICINA, UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE Y UN VEHICULO. PREFERIBLEMENTE, LA AZITROMICINA ESTA EN FORMA MUITIPARTICULADA EN LA QUE DICHO MULTIPARTICULADO COMPRENDE AZITROMICINA, UNA MEZCLA DE MONOBEHENATO DE GLICERILO, DIBEHENATO DE GLICERILO Y TRIBEHENATO DE GLICERILO Y UN POLOXAMERO. MBIÉN SE DESCRIBE UN PROCEDIMIENTO PARA REDUCIR LOS EFECTOS SECUNDARIOS GASTROINTESTINALES ASOCIADOS A LA ADMINISTRACION DE AZITROMICINA A UN MAMIFERO, QUE COMPRENDE LA ADMINISTRACION DE FORMA CONTIGUA DE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE A DICHO MAMIFERO EN EL QUE LA FRECUENCIA DE EFECTOS SECUNDARIOS GASTROINTESTINALES ES MENOR QUE LA QUE SE EXPERIMENTA ADMINISTRANDO UNA DOSIS IGUAL DE AZITROMICINA SIN DICHO AGENTE ALCALINIZANTE. ADEMAS SE DESCRIBE UN PROCEDIMIENTO PARA TRATAR UNA INFECCION BACTERIANA O PROTOZOARIA EN UN MAMÍFERO QUE LO NECESITE QUE COMPRENDE LA MINISTRACIÓN DE FORMA CONTIGUA A DICHO MAMÍFERO DE UNA DOSIS ÚNICA DE UNA FORMA DE DOSIFICACIÓN ORAL EN LA QUE DICHA FORMA DE DOSIFICACIÓN ORAL COMPRENDE AZITROMICINA Y UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE. ICIONALMENTE SE DESCRIBEN MULTIPARTICULADOS DE AZITROMICINA QUE COMPRENDEN AZITROMICINA, UN TENSIOACTIVO; Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRISEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/088-905-283-519-725,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,PENDING
106,EP,B1,EP 1537859 B1,156-637-530-486-526,2008-09-10,2008,EP 04252643 A,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin dosage forms with reduced side effects,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/156-637-530-486-526,Granted Patent,yes,6,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/16;;C07H17/00;;A61K9/00;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
107,EP,A3,EP 1537859 A3,002-476-466-737-693,2005-07-06,2005,EP 04252643 A,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,Azithromycin dosage forms with reduced side effects,"An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule. Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent. Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent. Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.",PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/002-476-466-737-693,Search Report,yes,6,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
108,BR,A,BR PI0403935 A,083-651-906-198-253,2005-08-09,2005,BR PI0403935 A,2004-05-14,IB 2004001654 W;;US 52708403 P;;US 76334004 A,2003-12-04,Formas de dosagem de azitromicina com efeitos colaterais reduzidos,"""FORMAS DE DOSAGEM DE AZITROMICINA COM EFEITOS COLATERAIS REDUZIDOS"". Uma forma de dosagem oral compreendendo azitromicina e um quantidade eficaz de um agente de alcalinização. Preferivelmente, a referida forma de dosagem oral compreende uma quantidade eficaz de um agente de alcalinização e um multiparticulado de azitromicina onde o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. Tipicamente, a forma de dosagem oral inclui quaisquer métodos de dosagem oral adequados tal como um pó para suspensão oral, uma embalagem ou sachê de dose única, um comprimido ou uma cápsula. Adicionalmente é descrita uma suspensão oral compreendendo azitromicina, uma quantidade eficaz de um agente de alcalinização e um veículo. Preferivelmente, a azitromicina é em forma de multiparticulado em que o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. é também descrito um método para reduzir efeitos colaterais gastrointestinais, associados com administração de azitromicina a um mamífero, compreendendo administrar contiguamente azitromicina e uma quantidade eficaz de agente de alcalinização ao referido mamífero em que a freq³ência de efeitos colaterais gastrointestinais é menor do que aquela experimentada administrando-se uma dose igual de azitromicina sem o referido agente de alcalinização. Além disso é descrito um método de tratar uma infecção bacteriana ou protozoária em um mamífero em necessidade deste compreendendo administrar contiguamente ao referido mamífero uma dose única de uma forma de dosagem oral em que a referida forma de dosagem oral compreende azitromicina e uma quantidade eficaz de um agente de alcalinização. Adicionalmente são descritos multiparticulados de azitromicina compreendendo azitromicina, um tensoativo; e um veículo farmaceuticamente aceitável.",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELISABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/083-651-906-198-253,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
109,SI,T1,SI 1537859 T1,120-095-560-943-695,2008-12-31,2008,SI 200430865 T,2004-05-06,US 52708403 P;;US 76334004 A;;EP 04252643 A,2003-12-04,Azithromycin dosage forms with reduced side effects,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/120-095-560-943-695,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,A61K9/00;;C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/00;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/00;;A61P31/04,,0,0,,,,ACTIVE
110,PE,A1,PE 20050573 A1,081-717-437-449-801,2005-09-05,2005,PE 2004000861 A,2004-09-07,US 52708403 P;;US 76334004 A,2003-12-04,FORMAS DE DOSIFICACION DE AZITROMICINA CON EFECTOS SECUNDARIOS REDUCIDOS,"SE REFIERE A UNA FORMA DE DOSIFICACION ORAL DE AZITROMICINA QUE COMPRENDE: a) AZITROMICINA EN FORMA DE LIBERACION INMEDIATA O MANTENIDA Y b) UNA CANTIDAD EFICAZ DE UN AGENTE ALCALINIZANTE. EL AGENTE ALCALINIZANTE COMPRENDE ADEMAS UNA SAL DE ALUMINIO, SAL DE MAGNESIO, SAL DE CALCIO, BICARBONATO, FOSFATO, SAL DE ARGININA, ENTRE OTROS. LA FORMULACION COMPRENDE MULTIPARTICULADOS DE AZITROMICINA EN LA QUE DICHOS MULTIPARTICULADOS CONTIENEN ADEMAS AZITROMICINA Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA FORMULACION COMPRENDE UN VEHICULO SELECCIONADO DE a) UNA CERA; b) UN GLICERIDO SELECCIONADO DE UNA MEZCLA DE MONOBEHENATO DE GLICERILO, DIBEHENATO DE GLICERILO ENTRE OTROS; c) UN POTENCIADOR DE DISOLUCION SELECCIONADO DE UN TENSIOACTIVO QUE CONSISTE DE POLAXAMEROS, DERIVADOS DE POLIOXIETILENO ESTERES DE ACIDOS GRASOS, ESTERES DE SORBITAN. LA FORMULACION PUEDE COMPRENDER DE 250 mg A 7g DE AZITROMICINA",PFIZER PROD INC,HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;THOMBRE AVINASH GOVIND;;FRIESEN DWAYNE THOMAS;;MCCRAY SCOTT BALDWIN;;CREW MARSHAL DAVID;;WEST JAMES BLAIR;;LYON DAVID KEITH;;APPEL LEAH ELIZABETH;;LO JULIAN BELKNAP,,https://lens.org/081-717-437-449-801,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
111,UY,A1,UY 28509 A1,093-075-889-706-075,2005-07-29,2005,UY 28509 A,2004-09-13,US 52708403 P;;US 76334004 A,2003-12-04,FORMAS DE DOSIFICACION DE AZITROMICINA CON EFECTOS SECUNDARIOS REDUCIDOS,"Dosificación oral que comprende azitromicina y una cantidad eficaz de un agente alcalinizante. Preferiblemente, dicha dosificación comprende una cantidad eficaz de un agente alcalinizante y un multiparticulado de azitromicina en el que dicho multiparticulado comprende azitromicina, una mezcla de monobehenato de glicerilo, dibehenato de glicerilo y tribehenato de glicerilo y un poloxámero. Una suspensión oral que comprende azitromicina, una cantidad eficaz de un agente alcalinizante y un vehículo. Preferiblemente, la azitromicina está en forma multiparticulada en la que dicho multiparticulado comprende azitromicina, una mezcla de monobehenato de glicerilo, debehenato de glicerilo y tribehenato de glicerilo y un poloxámero.",PFIZER PROD INC,CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;THOMBRE AVINASH GOVIND;;APPEL LEAH ELIZABETH;;MCCRAY SCOTT BALDWIN;;WEST JAMES BLAIR,,https://lens.org/093-075-889-706-075,Patent Application,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,DISCONTINUED
112,AT,T1,AT E407663 T1,125-949-270-120-736,2008-09-15,2008,AT 04252643 T,2004-05-06,US 52708403 P;;US 76334004 A,2003-12-04,AZITHROMYCIN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT VERRINGERTEN NEBENWIRKUNGEN,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HAGEN TIMOTHY ARTHUR;;HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;THOMBRE AVINASH GOVIND;;WEST JAMES BLAIR,,https://lens.org/125-949-270-120-736,Granted Patent,no,0,0,56,67,0,A61K9/143;;A61K9/1611;;A61K9/1617;;A61K9/1623;;A61K9/1635;;A61K9/1641;;A61K9/1694;;A61K9/2009;;A61K9/2013;;A61K9/2031;;A61K31/7052;;A61P31/00;;A61P31/04;;A61P33/00;;A61P33/02;;A61K31/7052;;A61K9/16;;A61K9/20;;A61K31/7042;;A61K9/1611;;A61K9/1641;;A61K31/7052;;A61K9/1635;;A61K9/2013;;A61K9/2031;;A61K9/2009;;A61K9/1617;;A61K9/1694;;A61K9/143;;A61K9/1623,C07H17/00;;A61K9/00;;A61K9/16;;A61K9/20;;A61K31/7052;;A61K47/02;;A61K47/14;;A61K47/18;;A61K47/44;;A61P31/04,,0,0,,,,ACTIVE
113,ZA,B,ZA 200604495 B,004-734-285-381-968,2008-03-26,2008,ZA 200604495 A,2006-06-01,US 52724403 P,2003-12-04,Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride,,PFIZER PROD INC,ELIZABETH APPEL LEAH;;DAVID CREW MARSHALL;;THOMAS FRIESEN DWAYNE;;MAX HERBIG SCOTT;;ROSS LEMOTT STEVEN;;BELKNAP LO JULIAN;;KEITH LYON DAVID;;BALDWIN MCCRAY SCOTT;;DIXON NEWBOLD DAVID;;JACK RAY RODERICK;;BLAIR WEST JAMES,,https://lens.org/004-734-285-381-968,Granted Patent,no,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K/;;A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,ACTIVE
114,EP,A1,EP 1701702 A1,150-127-175-741-909,2006-09-20,2006,EP 04798952 A,2004-11-22,IB 2004003839 W;;US 52724403 P,2003-12-04,SPRAY-CONGEAL PROCESS USING AN EXTRUDER FOR PREPARING MULTIPARTICULATE AZITHROMYCIN COMPOSITIONS CONTAINING PREFERABLY A POLOXAMER AND A GLYCERIDE,,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/150-127-175-741-909,Patent Application,yes,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/16;;A61K9/00;;A61K9/14;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,DISCONTINUED
115,KR,A,KR 20060109481 A,109-393-753-812-664,2006-10-20,2006,KR 20067011027 A,2006-06-05,US 52724403 P,2003-12-04,SPRAY-CONGEAL PROCESS USING AN EXTRUDER FOR PREPARING MULTIPARTICULATE AZITHROMYCIN COMPOSITIONS CONTAINING PREFERABLY A POLOXAMER AND A GLYCERIDE,Azithromycin multiparticulates containing acceptably low concentrations of azithromycin esters are formed by a melt-congeal process using an atomizer and extruder.,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/109-393-753-812-664,Patent Application,no,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/00;;A61K9/14;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,DISCONTINUED
116,WO,A1,WO 2005/053653 A1,135-820-484-365-179,2005-06-16,2005,IB 2004003839 W,2004-11-22,US 52724403 P,2003-12-04,SPRAY-CONGEAL PROCESS USING AN EXTRUDER FOR PREPARING MULTIPARTICULATE AZITHROMYCIN COMPOSITIONS CONTAINING PREFERABLY A POLOXAMER AND A GLYCERIDE,Azithromycin multiparticulates containing acceptably low concentrations of azithromycin esters are formed by a melt-congeal process using an atomizer and extruder.,PFIZER PROD INC;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/135-820-484-365-179,Patent Application,yes,9,12,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K31/7032;;A61K31/7052,,1,1,074-387-181-329-482,12927387;;10.1016/s0378-5173(03)00336-3,"SAVOLAINEN MARJA ET AL: ""Evaluation of polar lipid-hydrophilic polymer microparticles."", INTERNATIONAL JOURNAL OF PHARMACEUTICS. 27 AUG 2003, vol. 262, no. 1-2, 27 August 2003 (2003-08-27), pages 47 - 62, XP002325412, ISSN: 0378-5173",PENDING
117,BR,A,BR PI0416535 A,042-876-780-852-124,2007-01-09,2007,BR PI0416535 A,2004-11-22,US 52724403 P;;IB 2004003839 W,2003-12-04,processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo,"""PROCESSO DE CONGELAMENTO POR VAPORIZAçãO EMPREGANDO UM EXTRUSOR PARA PREPARAR COMPOSIçõES DE AZITROMICINA DE MULTIPARTICULADO CONTENDO PREFERIVELMENTE UM POLOXáMERO E UM GLICERìDEO"". Os multiparticulados de azitromicina contendo concentrações aceitavelmente baixas de ésteres de azitromicina são formados por um processo de fusão-congelabilidade.",PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/042-876-780-852-124,Patent Application,no,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,DISCONTINUED
118,CA,A1,CA 2547773 A1,128-286-240-626-976,2005-06-16,2005,CA 2547773 A,2004-11-22,US 52724403 P;;IB 2004003839 W,2003-12-04,SPRAY-CONGEAL PROCESS USING AN EXTRUDER FOR PREPARING MULTIPARTICULATE AZITHROMYCIN COMPOSITIONS CONTAINING PREFERABLY A POLOXAMER AND AGLYCERIDE,Azithromycin multiparticulates containing acceptably low concentrations of azithromycin esters are formed by a melt-congeal process using an atomizer a nd extruder.,PFIZER PROD INC,LYON DAVID KEITH;;RAY RODERICK JACK;;LEMOTT STEVEN ROSS;;MCCRAY SCOTT BALDWIN;;HERBIG SCOTT MAX;;NEWBOLD DAVID DIXON;;FRIESEN DWAYNE THOMAS;;WEST JAMES BLAIR;;CREW MARSHALL DAVID;;APPEL LEAH ELIZABETH;;LO JULIAN BELKNAP,,https://lens.org/128-286-240-626-976,Patent Application,no,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/16;;A61K9/00;;A61K9/14;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,DISCONTINUED
119,KR,A,KR 20080064209 A,021-150-659-610-882,2008-07-08,2008,KR 20087015425 A,2008-06-25,US 52724403 P,2003-12-04,SPRAY-CONGEAL PROCESS USING AN EXTRUDER FOR PREPARING MULTIPARTICULATE AZITHROMYCIN COMPOSITIONS CONTAINING PREFERABLY A POLOXAMER AND A GLYCERIDE,Azithromycin multiparticulates containing acceptably low concentrations of azithromycin esters are formed by a melt-congeal process using an atomizer and extruder.,PFIZER PROD INC,APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;LEMOTT STEVEN ROSS;;LO JULIAN BELKNAP;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;NEWBOLD DAVID DIXON;;RAY RODERICK JACK;;WEST JAMES BLAIR,,https://lens.org/021-150-659-610-882,Patent Application,no,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/16;;A61K9/00;;A61K9/14;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,DISCONTINUED
120,NO,L,NO 20062389 L,063-432-677-610-914,2006-06-16,2006,NO 20062389 A,2006-05-24,US 52724403 P;;IB 2004003839 W,2003-12-04,Fremgangsmate for spray-storkning ved anvendelse av en ekstruder for fremstilling av multipartikkulaere azitromycinmaterialer,Det beskrives azitromycin-multipartikkulater inneholdende akseptabelt lave konsentrasjoner av azitromycinestere produsert med en smelte-størkne-prosess.,PFIZER PROD INC,HERBIG SCOTT MAX;;LO JULIAN BELKNAP;;APPEL LEAH ELIZABETH;;CREW MARSHALL DAVID;;FRIESEN DWAYNE THOMAS;;LYON DAVID KEITH;;MCCRAY SCOTT BALDWIN;;RAY RODERICK JACK;;WEST JAMES BLAIR;;NEWBOLD DAVID DIXON;;LEMOTT STEVEN ROSS,,https://lens.org/063-432-677-610-914,Abstract,no,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/16;;A61K9/00;;A61K9/14;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,DISCONTINUED
121,AU,A1,AU 2004/294813 A1,132-066-531-076-687,2005-06-16,2005,AU 2004/294813 A,2004-11-22,US 52724403 P;;IB 2004003839 W,2003-12-04,Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride,,PFIZER PROD INC,LYON DAVID KEITH;;NEWBOLD DAVID DIXON;;CREW MARSHALL DAVID;;APPEL LEAH ELIZABETH;;RAY RODERICK JACK;;LEMOTT STEVEN ROSS;;MCCRAY SCOTT BALDWIN;;LO JULIAN BELKNAP;;FRIESEN DWAYNE THOMAS;;HERBIG SCOTT MAX;;WEST JAMES BLAIR,,https://lens.org/132-066-531-076-687,Patent Application,no,0,0,16,16,0,A61K9/0095;;A61K9/145;;A61K9/1617;;A61K9/1641;;A61K9/1694;;A61K31/7032;;A61K31/7052;;A61P31/04;;A61K9/16;;A61K9/145;;A61K31/7032;;A61K9/0095;;A61K31/7052;;A61K9/1617;;A61K9/1641;;A61K9/1694,A61K9/00;;A61K9/14;;A61K9/16;;A61K31/00;;A61K31/7032;;A61K31/7052,,0,0,,,,DISCONTINUED
